false
--12-31
0001851484
0001851484
2024-08-12
2024-08-12
0001851484
dei:FormerAddressMember
2024-08-12
2024-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
August 12, 2024
Citius Oncology, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-41534 |
|
99-4362660 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
11 Commerce Drive, 1st Floor, Cranford, NJ |
|
07016 |
|
|
(Address of principal executive offices) |
|
(Zip Code) |
|
Registrant’s telephone number, including
area code: (908) 967-6677
TenX Keane Acquisition
420 Lexington Avenue, Suite 2446
New York, NY 10170
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock |
|
CTOR |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Introductory Note
As used in this Current Report
on Form 8-K, unless otherwise stated or the context clearly indicates otherwise, the terms the “Company,” “Registrant,”
“we,” “us” and “our” refer to the entity formerly named TenX Keane Acquisition, a Cayman Islands exempted
company (“TenX”), as renamed Citius Oncology, Inc. in connection with the Domestication (as defined below), and after giving
effect to the Business Combination (as defined below).
On August 12, 2024 (the “Closing
Date”), the Company completed the previously announced business combination (the “Closing”) pursuant to that certain
Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023 (the “Merger Agreement”), by and among Citius
Pharmaceuticals, Inc., a Nevada corporation (“Citius Pharma”), Citius Oncology, Inc., a Delaware corporation (now known as
Citius Oncology Sub, Inc., “SpinCo”), TenX (now Citius Oncology, Inc., a Delaware corporation) and TenX Merger Sub, Inc.,
a Delaware corporation and wholly-owned subsidiary of TenX (“Merger Sub”), and the related transaction documents described
therein (the “Business Combination”).
As contemplated by the Merger
Agreement and described in the section entitled “Proposal 1 — The Business Combination Proposal” beginning on
page 111 of the final proxy statement/prospectus supplement (File No. 333-275506) (the “Final Prospectus”), filed on July
12, 2024, with the Securities and Exchange Commission (the “SEC”), on or prior to the Closing Date the following occurred:
| i. | Effective August 5, 2024, TenX’s jurisdiction of incorporation was changed by its deregistering
as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State
of Delaware (the “Domestication”). In connection with the consummation of the Domestication, TenX changed its name to “Citius
Oncology, Inc.” pursuant to the filing of a certificate of incorporation (the “Company Charter”) and adopted bylaws
(the “Company Bylaws”). |
| ii. | As a result of and upon the effective time of the Domestication, (i) each then-issued and outstanding
ordinary share, par value $0.0001 per share, of TenX (“TenX Ordinary Shares”), converted automatically, on a one-for-one basis,
into shares of common stock, par value $0.0001 per share, of the Company (“Company Common Stock”); (ii) each then-issued and
outstanding right to receive two-tenths of one share of TenX Ordinary Shares (“TenX Rights”) converted automatically into
a right to receive two-tenths of one share of Company Common Stock (“Company Rights”); and (iii) each then-issued and outstanding
unit of TenX (“TenX Units”) was canceled and each holder was entitled to one share of Company Common Stock and one Company
Right. For further details, see “Proposal No. 2 — The Domestication Proposal” beginning on page 154
of the Final Prospectus. |
| iii. | Following the above steps, Merger Sub merged with and into SpinCo (the “Merger”), with SpinCo
continuing as the surviving company in the Merger and a wholly-owned subsidiary of the Company. As a result of the Merger, the existing
common stock of SpinCo, par value $0.0001 per share (“SpinCo Common Stock”), automatically converted into the right to receive
shares of Company Common Stock in accordance with an exchange ratio described below. |
| iv. | Upon Closing, Citius Pharma (formerly SpinCo’s sole shareholder) received 65,627,262 shares of Company
Common Stock. In addition, upon Closing, Maxim Group received 1,872,738 shares of Company Common Stock and Newbridge Securities received
50,000 shares of Company Common Stock, in each case as payment of financial advisory fees. All options to purchase shares of SpinCo Common
Stock (“SpinCo Options”) were converted into options to purchase shares of Company Common Stock (“Company Options”). |
| v. | All closing conditions as referenced in the Merger Agreement have either been met or waived by the parties. Certain closing conditions
that were waived by the parties, pursuant to the Merger Agreement, include, but are not limited to: (i) Section 7.18(a) and 7.18(b), which
(a) required Citius Pharma to transfer the LYMPHIRTM (denileukin diftitox) trademark to the Company prior to Close and (b)
required Citius Pharma to send a letter notifying the FDA that all ownership rights of the BLA and IND will transfer from the Citius Pharma
to the Company within five business days of Citius Pharma’s receipt of the Notice of Approval for LYMPHIR from the U.S. Food &
Drug Administration, which transfers will instead occur within 60 days following the Closing, and (ii) Section 2.3(f), which waiver provided
that the $10,000,000 in cash Citius Pharma contributed to the Company was to be comprised of $3,800,111
in working capital of SpinCo post-Closing, funding $6,199,889 of transaction expenses of the parties to the Merger Agreement, and $1,077,026
for the purchase of TenX rights prior to the Closing of the transaction (which converted into 422,353 shares of Company Common Stock at
Closing) (in the aggregate, the “Capital Contribution”). |
| vi. | Pursuant to the Merger Agreement and the Sponsor Support Agreement entered into concurrently with the
execution of the Merger Agreement, the Company issued 119,500 shares of Company Common Stock to the Sponsor (as defined below) for amounts
outstanding under the promissory notes TenX issued to the Sponsor on July 18, 2023 and October 18, 2023. Both of the promissory notes
issued to the Sponsor evidenced deposits into the Trust Account (as defined in the Merger Agreement) to extend the timeline to complete
a business combination. |
| vii. | Immediately after the Closing, the Company issued a promissory note to the Sponsor, dated August 12, 2024,
for $1,288,532 of transaction expenses, which automatically converted into 128,854 shares of Company Common Stock on August 13, 2024. |
After the Closing, Citius
Pharma continues to control a majority of the voting power for the election of directors of the Company, owning approximately 92.6% of
the outstanding shares of Company Common Stock. As a result, the Company is a “controlled company” within the meaning of the
rules of The Nasdaq Stock Market LLC (‘‘Nasdaq’’) and may elect not to comply with certain corporate governance
standards. While the Company does not presently intend to rely on these exemptions, the Company may opt to utilize these exemptions in
the future as long as it remains a controlled company.
As of the open of trading
on August 13, 2024, the Company Common Stock began trading on The Nasdaq Capital Market as “CTOR”. The Company does not have
units or rights traded following the completion of the Business Combination.
Immediately
following the Business Combination, the Company’s ownership was as follows:
| ● | TenX’s
former public shareholders owned approximately 1.3% of the outstanding shares of Company Common Stock; |
| ● | Citius
Pharma owned approximately 92.6% of the outstanding shares of Company Common Stock; and |
| ● | 10XYZ
Holdings LP, a Delaware limited partnership and shareholder of TenX (the “Sponsor”) and related parties collectively owned
approximately 3.1% of Company Common Stock. |
These percentages exclude all Company Options
that may be exercisable for shares of Company Common Stock.
Certain terms used in this
Current Report on Form 8-K have the same meaning as set forth in the Final Prospectus. This Current Report on Form 8-K contains summaries
of the material terms of various agreements executed in connection with the transactions described herein. The summaries of these agreements
are subject to, and are qualified in their entirety by, reference to these agreements, which are filed as exhibits hereto and incorporated
herein by reference.
Item 1.01. Entry into a Material Definitive Agreement.
The information set forth in the “Introductory Note” above
is incorporated into this Item 1.01 by reference.
Amended &Restated Registration Rights Agreement
On August 12, 2024, in connection
with the Closing and as contemplated by the Merger Agreement, the Company, Sponsor Equityholders and the Legacy Citius Oncology Equityholder
(each defined therein) entered into the Amended and Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”).
The material terms of the A&R Registration Rights Agreement are described in the section entitled “Proposal No. 1 —
The Business Combination Proposal — Summary of the Ancillary Agreements — Amended & Restated Registration Rights Agreement”
beginning on page 131 of the Final Prospectus. In addition, in a term agreed to in connection with the Closing, the Company agreed to
use its commercially reasonable efforts to file a registration statement for the resale of any or all of an individual holder’s
registrable securities, as requested in writing by such holder, within 120 days of the date of the A&R Registration Rights Agreement.
The description of the A&R Registration Rights Agreement herein is qualified in its entirety by the text of the A&R Registration
Rights Agreement, which is included as Exhibit 10.1 to this Report and is incorporated herein by reference.
Amended & Restated Shared Services Agreement
On August 12, 2024, in connection
with the Closing and as contemplated by the Merger Agreement, SpinCo and Citius Pharma entered into the Amended and Restated Shared Services
Agreement (the “A&R Shared Services Agreement”). The material terms of the A&R Shared Services Agreement are described
in the section entitled “Proposal No. 1 — The Business Combination Proposal — Summary of the Ancillary Agreements
— Amended & Restated Shared Services Agreement” beginning on page 131 of the Final Prospectus. Such description is
qualified in its entirety by the text of the A&R Shared Services Agreement, which is included as Exhibit 10.2 to this Report and is
incorporated herein by reference.
Letter Agreement to the Merger Agreement
On August 12, 2024, in connection
with the Closing, the parties to the Merger Agreement entered into a letter agreement waiving certain closing conditions of the Merger
Agreement (the “Letter Agreement”). The material terms of the Letter Agreement are set forth in the “Introductory Note”
above and are incorporated into this Item 1.01 by reference. The foregoing description of the Letter Agreement does not purport to be
complete and is qualified in its entirety by the text of the Letter Agreement, which is incorporated by reference to this Current Report
on Form 8-K as Exhibit 10.8.
Promissory Note between the Company and Citius
Pharma
On August 12, 2024, Citius
Pharma made the Capital Contribution to the Company, as set forth in the “Introductory Note” above. Such Capital Contribution
is evidenced by an unsecured promissory note (the “Note”) issued by the Company, dated August 16, 2024, in the principal amount
of $3,800,111 to Citius Pharma. The Note bears no interest and is repayable in full upon a financing of at least $10 million by the Company,
per the terms of the Note. The foregoing description of the Note does not purport to be complete and is qualified in its entirety by the
text of the Note, which is incorporated by reference to this Current Report on Form 8-K as Exhibit 10.9.
Item 2.01. Completion of Acquisition or Disposition of Assets.
The information set forth
in the “Introductory Note” above is incorporated into this Item 2.01 by reference. TenX held a special meeting of stockholders
on August 2, 2024, to approve, among other things, the Business Combination (the “Special Meeting”). The stockholders approved
the Business Combination at the Special Meeting, and the Business Combination was completed on August 12, 2024.
As a result of the
Closing (after giving effect to the Domestication), among other things, (i) all outstanding shares of capital stock of SpinCo, other
than Treasury Shares, were canceled in exchange for the right to receive, in the aggregate, 67,500,000 shares of Company Common
Stock and (ii) all outstanding SpinCo Options were assumed by the Company and converted into Company Options. The Treasury Shares
were canceled and ceased to exist, and no stock or other consideration was issued in respect of the Treasury Shares. Specifically,
each share of SpinCo Common Stock was canceled and converted into the right to receive a number of shares of Company Common Stock
equal to the Base Exchange Ratio, which is the quotient obtained by dividing (x) 67,500,000 by (y) 67,500,000, the aggregate number
of shares of SpinCo Common Stock outstanding as of immediately prior to the effective time. Each outstanding SpinCo Option was
exchanged for a number of Company Options (rounded down to the nearest whole share) equal to the number of shares of SpinCo Common
Stock subject to such option, multiplied by the Base Exchange Ratio, and the exercise price per share was the exercise price in
effect immediately prior to the effective time, divided by the Base Exchange Ratio (rounded up to the nearest full cent).
In addition, at the Closing,
every five outstanding Company Rights automatically converted into one share of Company Common Stock.
In connection with the Domestication,
(i) each then-issued and outstanding TenX Ordinary Share, converted automatically, on a one-for-one basis, into a share of Company Common
Stock; (ii) each then-issued and outstanding TenX Right converted into a Company Right; and (iii) each then-issued and outstanding TenX
Unit was canceled and the holder thereof was issued one share of Company Common Stock and one Company Right.
In connection with the Business
Combination, Holders of 4,297,828 TenX Ordinary Shares sold in TenX’s initial public
offering properly exercised their rights to have such shares redeemed for a pro rata portion of the trust account holding the proceeds
from TenX’s initial public offering, or approximately $11.47 per share and $49,296,087.16
in the aggregate. The remaining balance immediately prior to the Closing of approximately $163,498.89 remained in the trust account,
which was used to pay certain expenses in connection with the Business Combination.
Upon the Closing, 71,304,049
shares of Company Common Stock were issued and outstanding. After the Closing Date, the TenX Ordinary
Shares, TenX Units and TenX Rights ceased trading on The Nasdaq Global Market under the symbols “TENK,” “TENKU”
and “TENKR” respectively, and Company Common Stock commenced trading on The Nasdaq Capital Market under the symbol “CTOR”
on August 13, 2024.
The material terms and conditions
of the Merger Agreement are described in the section entitled “Proposal No. 1 — The Business Combination Proposal — Consideration”
beginning on page 111 of the Final Prospectus and are incorporated herein by reference.
FORM 10 INFORMATION
Item 2.01(f) of Form 8-K provides that if the predecessor
registrant was a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)), as TenX was immediately before the Business Combination, then the registrant must disclose the information
that would be required if the registrant were filing a general form for registration of securities on Form 10. As a result of the consummation
of the Business Combination, and as discussed below in Item 5.06 of this Report, the Company has ceased to be a shell company. Accordingly,
the Company is providing the information below that would be included in a Form 10 if it were to file a Form 10. Please note that the
information provided below relates to the combined company after the consummation of the Business Combination, unless otherwise specifically
indicated or the context otherwise requires.
Forward-Looking Statements
Some of the information
contained in this Current Report on Form 8-K, or incorporated herein by reference, contains forward-looking statements. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not
forward-looking. All statements other than statements of historical fact contained in or incorporated by reference into this Report,
including the expected benefits of the Business Combination, the U.S. federal income tax consequences of the Business Combination,
the Company’s future results of operations, financial position and business strategy and its expectations regarding the
application of, and the commercialization of and market for LYMPHIRTM and any future product candidates, the potential
for and timing of any milestones and royalties under the Company’s license agreements with partners, are forward-looking
statements.
The forward-looking statements
contained in this Form 8-K and in any document incorporated by reference are based on current expectations and beliefs concerning future
developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will
be those that the Company has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are
beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from
those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those
factors described under the heading “Risk Factors”
and the following:
| ● | the
inability of the Company to recognize the anticipated benefits of the Business Combination,
which may not be realized fully, if at all, or may take longer to realize than expected; |
| ● | the
Company’s need for substantial additional funds; |
| ● | the
historical combined financial data and pro forma financial statements included herein may
not be representative of the results the Company would have achieved as a standalone company
and may not be a reliable indicator of its future results; |
| ● | the
ability of the Company to commercialize LYMPHIR; |
| ● | the
ability of LYMPHIR or any of our future product candidates to impact the quality of life
of our target patient populations; |
| ● | the
estimated markets for LYMPHIR or any of our future product candidates and the acceptance
thereof by any market; |
| ● | risks
relating to the results of research and development activities, including those from our
existing and any new pipeline assets; |
| ● | our
ability to obtain, perform under and maintain financing and strategic agreements and relationships; |
| ● | the
Company’s operating results and financial performance; |
| ● | uncertainties
relating to preclinical and clinical testing, approval and commercialization of any future
product candidates by the Company; |
| ● | our
ability to procure cGMP commercial-scale supply; |
| ● | our
dependence on third-party suppliers; |
| ● | the
Company’s ability to manage and grow its business and execution of its business and
growth strategies; |
| ● | risks
arising from changes in the fields in which LYMPHIR and any of our future product candidates,
if approved, may compete; |
| ● | the
competitive environment in the life sciences and biotechnology industry; |
| ● | failure
to maintain, protect and defend the Company’s intellectual property rights; |
| ● | changes
in government laws and regulations, including laws governing intellectual property, and the
enforcement thereof affecting the Company’s business; |
| ● | changes
in general economic conditions, geopolitical risk, including as a result of any pandemic
or international conflict, including in the Middle East and between Russia and Ukraine; |
| ● | the
outcome of any litigation related to or arising out of the Business Combination, or any adverse
developments therein or delays or costs resulting therefrom; |
| ● | the
effect of the transactions on the Company’s business relationships, operating results,
and businesses generally; |
| ● | the
ability of the Company to meet Nasdaq’s continued listing standards following the Business
Combination; and |
| ● | the
volatility in the price of the Company’s securities due to a variety of factors, including
the Company’s inability to implement their business plans or meet or exceed its financial
projections. |
Should
one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results
may vary in material respects from those projected in these forward-looking statements. The Company does not undertake any obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as may be required under applicable securities laws. You should not place undue reliance on any forward-looking statements, which are
based only on information currently available to the Company.
Business
The information set forth
in the section entitled “Information About the SpinCo Business” beginning on page 192 of the Final Prospectus is incorporated
herein by reference.
Risk Factors
The information set forth
in the section entitled “Risk Factors and Risk Factor Summary” beginning on page 59 of the Final Prospectus is incorporated
herein by reference.
Financial Information
Reference
is made to the disclosure set forth in Item 9.01 of this Current Report on Form 8-K concerning the financial information of
the Company and such information is incorporated herein by reference.
Management’s Discussion and Analysis of Financial Condition
and Results of Operations and Quantitative and Qualitative Disclosures About Market Risk
The disclosure contained in the Final Prospectus in the section entitled
“SpinCo Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on page 204
of the Final Prospectus is incorporated herein by reference.
Description of Property
Pursuant to the shared services
agreement, during the nine months ended June 30, 2024, the Company paid Citius Pharma for the use of shared office space located at 11
Commerce Drive, First Floor, Cranford, New Jersey 07016. The lease held by Citius Pharma runs until October 31, 2025.
Security Ownership of Certain Beneficial Owners and Management
The following table and accompanying
footnotes set forth information regarding beneficial ownership of Company Common Stock following the consummation of the Business Combination
by:
|
● |
each person known by us to be the beneficial owner of more than 5% of outstanding Company Common Stock; |
|
|
|
|
● |
each of our executive officers and directors; and |
|
|
|
|
● |
all our executive officers and directors as a group. |
Beneficial ownership for the
purposes of the following table is determined in accordance with the rules and regulations of the SEC. A person is a “beneficial
owner” of a security if that person has or shares “voting power,” which includes the power to vote or to direct the
voting of the security, or “investment power,” which includes the power to dispose of or to direct the disposition of the
security or has the right to acquire such powers within 60 days of August 13, 2024.
Unless otherwise noted in the
footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have
sole voting and investment power with respect to their beneficially owned Company Common Stock. The
beneficial ownership of the Company after the Business Combination is based on 71,304,049 Company
Common Stock issued and outstanding after the Closing.
Name and Address of Beneficial Owner(1) | |
Number of Shares | | |
% of Ownership | |
Directors and executive officers of the Company | |
| | |
| |
Myron Holubiak(2) | |
| 500,000 | | |
| 1.70 | % |
Leonard Mazur(3) | |
| 1,233,333 | | |
| * | |
Jaime Bartushak(4) | |
| 466,667 | | |
| * | |
Myron Czuczman(5) | |
| 466,667 | | |
| * | |
Suren Dutia(6) | |
| 150,000 | | |
| * | |
Eugene Holuka(7) | |
| 150,000 | | |
| * | |
Joel Mayersohn | |
| – | | |
| – | |
Dennis McGrath(8) | |
| 150,000 | | |
| * | |
Robert Smith | |
| – | | |
| – | |
Carol Webb(9) | |
| 150,000 | | |
| * | |
All directors and executive officers of New Citius Oncology after consummation of the Business Combination, as a group (ten individuals) | |
| 3,266,667 | | |
| 4.4 | % |
| |
| | | |
| | |
5% Holders | |
| | | |
| | |
Citius Pharmaceuticals, Inc. | |
| 66,049,615 | | |
| 92.6 | % |
| (1) | The business address of each of the following entities or individuals
is c/o of the Company, 11 Commerce Drive, 1st Floor, Cranford, New Jersey 07016. |
| (2) | Consists of 500,000 shares of New Citius Oncology Common Stock
Mr. Holubiak has the right to acquire pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
| (3) | Consists of 1,233,333 shares of New Citius Oncology Common
Stock Mr. Mazur has the right to acquire pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
| (4) | Consists of 466,667 shares of New Citius Oncology Common Stock
Mr. Bartushak has the right to acquire pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
| (5) | Consists of 466,667 shares of New Citius Oncology Common Stock Mr. Czuczman has the right to acquire
pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
| (6) | Consists of 150,000 shares of New Citius Oncology Common Stock
Mr. Dutia has the right to acquire pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
| (7) | Consists of 150,000 shares of New Citius Oncology Common Stock
Dr. Holuka has the right to acquire pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
| (8) | Consists of 150,000 shares of New Citius Oncology Common Stock
Mr. McGrath has the right to acquire pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
| (9) | Consists of 150,000 shares of New Citius Oncology Common Stock
Ms. Webb has the right to acquire pursuant to outstanding options that are exercisable within 60 days of August 13, 2024. |
Directors and Executive Officers
Information with respect to
the Company’s directors and executive officers immediately after the Closing is set forth in the section entitled “Management
of New Citius Oncology After the Business Combination” beginning on page 213 in the Final Prospectus and Item 5.02 of this Current
Report on Form 8-K and is incorporated herein by reference.
The size of the Company’s
board of directors is eight members. Each of Mr. Myron Holubiak (Class I), Mr. Joel Mayersohn (Class I), Dr. Eugene Holuka (Class II),
Mr. Robert Smith (Class II), Ms. Carol Webb (Class II), Mr. Suren Dutia (Class III), Mr. Leonard Mazur (Class III and Chairman) and Mr.
Dennis McGrath (Class III) were elected to serve as directors of the Company. In accordance with the Certificate of Incorporation of the
Company, each was elected to serve in staggered terms until the 2025 (Class I), 2026 (Class II) and 2027 (Class III) annual meetings of
stockholders, as applicable, or until their respective successors are duly elected or until their earlier death, resignation, retirement
or removal for cause.
The Board appointed Messrs.
McGrath, Dutia and Smith to serve on the Audit and Risk Committee, with Mr. McGrath serving as its chair. The Board appointed Mr. Dutia,
Dr. Holuka and Ms. Webb to serve on the Compensation Committee, with Mr. Dutia serving as its chair. The Board appointed Dr. Holuka, Mr.
McGrath and Ms. Webb to serve on the Nominating and Corporate Governance Committee, with Dr. Holuka serving as its chair.
In connection with the completion
of the Business Combination, Mr. Mazur was appointed to serve as the Company’s Chief Executive Officer and Chair of the board of
directors, Mr. Bartushak was appointed to serve as the Company’s Chief Financial Officer, Mr. Holubiak was appointed to serve as
the Company’s Secretary and Treasurer and Mr. Czuczman was appointed to serve as the Company’s Chief Medical Officer.
Executive and Director Compensation
The information set forth
in the section entitled “Executive and Director Compensation of SpinCo” beginning on page 210 of the Final Prospectus,
which includes the executive compensation information of SpinCo, is incorporated herein by reference.
Certain Relationships and Related Transactions
The information set forth
in the section entitled “Certain Relationships and Related Party Transactions” beginning on page 223 of the Final Prospectus
is incorporated herein by reference.
Director Independence
After review of all relevant
transactions or relationships between each nominee for director, or any of his or her family members, and the Company, its senior management
and Wolf & Company, P.C., its independent registered public accounting firm, the board of directors has determined that all directors
of the Company are independent within the meaning of the applicable Nasdaq listing standards, except Leonard Mazur, the Chief Executive
Officer and Chairman, Myron Holubiak, the Executive Vice President and Joel Mayersohn.
Because Citius Pharma continues
to control a majority of the voting power of the outstanding shares of Company Common Stock, the Company qualifies as a “controlled
company” within the meaning of the corporate governance standards of the Nasdaq. Under these rules, a listed company of which more
than 50% of the voting power is held by an individual, group or another company is a “controlled company” and may elect not
to comply with certain corporate governance requirements, including the requirements that (i) a majority of the Board consist of “independent
directors” as defined under Nasdaq listing rules, (ii) we have a compensation committee composed entirely of independent directors
and (iii) we have a nominating/corporate governance committee composed entirely of independent directors.
The Company does not intend
to rely on these exemptions, but may opt to utilize these exemptions in the future as long as it remains a controlled company. Accordingly,
Company stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate
governance requirements of Nasdaq.
If the Company ceases to be
a “controlled company” in the future, it will be required to comply with the Nasdaq Listing Rules, which may require replacing
a number of its directors and may require development of certain other governance-related policies and practices. These and any other
actions necessary to achieve compliance with such rules may increase the Company’s legal and administrative costs, will make some
activities more difficult, time-consuming, and costly and may also place additional strain on the Company’s personnel, systems and
resources.
Legal Proceedings
There is no material litigation,
arbitration or governmental proceeding currently pending against the Company or any members of the Company’s management team in
their capacity as such, and the Company and the members of the Company’s management team have not been subject to any such proceeding
in the twelve (12) months preceding the date of this filing.
Market Price of and Dividends on the Registrant’s Common Equity
and Related Stockholder Matters
Market Information and Market Price
Prior to the Closing Date, the
TenX Units, TenX Ordinary Shares, and TenX Rights were each traded on The Nasdaq Global Market under the symbols “TENKU,”
“TENK” and “TENKR” respectively. Upon the Closing, the Company’s Common Stock began trading on the Nasdaq
Capital Market under the symbol “CTOR”. As of August 13,
2024, following the completion of the Business Combination, there were 71,304,049 shares
of Company Common Stock issued and outstanding.
Holders
As of August 14, 2024, there
were six holders of record of Company Common Stock. The Company does not have any outstanding units or rights following the Business Combination.
Dividends
The Company has not paid
any cash dividends on shares of its common stock to date and does not intend to for the foreseeable future as it focuses on the
development and commercialization of its product candidates. The payment of cash dividends by the Company in the future will be
dependent upon its revenues and earnings, if any, capital requirements and general financial conditions. The payment of any cash
dividends is within the discretion of the Company Board.
Additional
information set forth in the section entitled “Market Price and Dividend Information” beginning on page 49 of
the Final Prospectus is incorporated herein by reference.
Recent Sales of Unregistered Securities
The information set forth
under Item 3.02 of this Current Report on Form 8-K is incorporated herein by reference.
Description of Registrant’s Securities
The description of the Company’s
securities is contained in the section entitled “Description of Combined Company Securities” beginning on page 227
of the Final Prospectus and is incorporated herein by reference.
Indemnification of Directors and Officers
Information
about the indemnification of the Company’s directors and officers is set forth in the section entitled “Description of
Combined Company Securities — Limitations of Liability and Indemnification Matters” on page 232 of the Final Prospectus
and is incorporated herein by reference.
Financial Statements, Supplementary Data and Exhibits
The information set forth
under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
As described in the Introductory
Note above, pursuant to the Merger Agreement and the Sponsor Support Agreement and in connection with the closing of the Business Combination,
on August 13, 2024, the Company issued 119,500 shares of Common Stock to the Sponsor for amounts outstanding under the promissory notes
TenX issued to the Sponsor on July 18, 2023 ($660,000) and October 18, 2023 ($535,000). The promissory notes issued to the Sponsor on
July 18, 2023 and October 18, 2023 evidenced deposits into the Trust Account (as defined in the Merger Agreement) to extend the timeline
to complete a business combination.
In connection with the closing
of the Business Combination, Citius Pharma issued a promissory note to the Sponsor for the reimbursement of $1,288,532 in transaction
and other expenses. Pursuant to its terms, the note converted automatically on August 13, 2024, the day after the closing, into 128,854
shares of Company Common Stock.
The issuances of shares of
Common Stock to the Sponsor described herein were made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities
Act of 1933, as amended.
Item 3.03 Material Modification to Rights of Security Holders.
On the Closing Date, in connection
with the consummation of the Business Combination, TenX adopted the Company Charter and the Company Bylaws. The material terms of each
of the Company Charter and the Company Bylaws and the general effect upon the rights of holders of TenX’s capital stock are included
in the sections entitled “Proposal No. 3 — The Organizational Documents Proposal” beginning on page 156 and “Comparison
of Corporate Governance and Shareholder Rights” beginning on page 234 of the Final Prospectus and are incorporated herein by
reference.
The
foregoing description of the Company Charter and Company Bylaws is not complete and is qualified in its entirety by reference to the text
of the Company Charter and Company Bylaws, which are included as Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on
Form 8-K, and are incorporated herein by reference.
Item 4.01. Changes in Registrant’s Certifying Accountant.
(a) Effective August 13, 2024,
Marcum LLP (“Marcum”), TenX’s independent registered public accounting firm prior to the Business Combination, was dismissed
and replaced as the Company’s independent registered public accounting firm.
Marcum’s report on TenX’s
consolidated balance sheets as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in shareholders’
equity (deficit) and cash flows for each of the two years in the period ended on December 31, 2023, and the related notes (collectively
referred to as the “financial statements”) did not contain any adverse opinion or disclaimer of opinion, nor were they qualified
or modified as to uncertainty, audit scope or accounting principles, except for the substantial doubt about the Company’s ability
to continue as a going concern.
During
the period from March 1, 2021 (inception), through December 31, 2023, and subsequent
interim periods through August 12, 2024, there were no disagreements between TenX and Marcum
on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements,
if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreement in
connection with its report covering such period or “reportable events” (as that term is defined in Item 304(a)(1)(v) of Regulation
S-K), except that Marcum concurred with the Company’s assessment of a material weakness related to the Company’s internal
controls over financial reporting, due to material weaknesses in internal control over financial reporting that existed relating to accounting
for accruals and advances from related parties and accounting for complex financial instruments.
The
Company provided Marcum with a copy of the disclosures made by the Company in response to this Item 4.01 and requested that Marcum furnish
the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company in response to this Item
4.01 and, if not, stating the respects in which it does not agree. The letter from Marcum is included as Exhibit 16.1 to this Current
Report.
(b) Effective August 13, 2024,
Wolf & Company, P.C. (“Wolf”) was engaged as the Company’s independent registered public accounting firm to audit
the Company’s consolidated financial statements as of and for the year ending September 30, 2024. Wolf has served as the independent
registered public accounting firm of the Citius Pharma prior to the Business Combination. During the years ended September 30, 2023 and
2022, and subsequent interim period through August 12, 2024, the Company did not consult with Wolf with respect to (i) the application
of accounting principles to a specified transaction, either completed or proposed, the type of audit opinion that might be rendered on
its financial statements, and neither a written report nor oral advice was provided to the Company that Wolf concluded was an important
factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any other
matter that was the subject of a disagreement or a reportable event (each as defined above).
Item 5.01. Changes in Control of Registrant.
The information set forth
under in the section entitled “Proposal No. 1 — The Business Combination Proposal” beginning on page 111 of the
Final Prospectus and “Introductory Note” and Item 2.01 in this Current Report on Form 8-K is incorporated herein by reference.
There are no known arrangements
which may at a subsequent date result in a further change in control of the Company.
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Election of Directors and Appointment of Officers
Information with respect
to the Company’s directors and executive officers immediately after the Closing is set forth in the section entitled
“Management of New Citius Oncology After the Business Combination” beginning on page 213 in the Final Prospectus
and Item 5.02 of this Current Report on Form 8-K and is incorporated herein by reference. The
information contained in Item 1.01 and Item 2.01 of this Current Report on Form 8-K is also incorporated herein by
reference.
Biographical information with
respect to each such director and officer is set forth in the section entitled “Management of PubCo After the Business Combination”
beginning on page 213 of the Final Prospectus and is incorporated herein by reference.
Departure of Directors and Certain Officers
In connection with the Business
Combination, effective as of the Closing, each of Xiaofeng Yuan, Taylor Zhang, Cathy Jiang and Brian Hartzband resigned as directors and
executive officers of TenX. Xiaofeng Yuan resigned as Chief Executive Officer and Chairman of the Board, Taylor Zhang resigned as Chief
Financial Officer and a director and each of Cathy Jiang and Brian Hartzband resigned as directors. Mr. Mayersohn will continue as a Class
I Director of the Company.
2024 Omnibus Stock Incentive Plan
On August 12, 2024, the Citius
Oncology, Inc. 2024 Omnibus Stock Incentive Plan (the “2024 Plan”) became effective. The 2024 Plan was approved by TenX’s
stockholders at the Special Meeting on August 2, 2024.
The information set forth
in the section entitled “Proposal No. 6 — The Incentive Plan Proposal” beginning on page 164 of the Final Prospectus
is incorporated herein by reference. The foregoing description of the 2024 Plan and the information incorporated by reference in the preceding
sentence does not purport to be complete and is qualified in its entirety by the terms and conditions of the 2024 Plan, which is incorporated
by reference to this Current Report on Form 8-K as Exhibit 10.3.
Item 5.03. Amendments to Memorandum and
Articles of Association; Change in Fiscal Year.
The information contained
in Item 3.03 of this Current Report on Form 8-K is incorporated in this Item 5.03 by reference.
In connection with the Closing
of the Business Combination, the Company changed its fiscal year end from December 31 to September 30, the fiscal year end of SpinCo prior
to the Business Combination.
Item 5.06. Change in Shell Company Status.
As a result of the Business
Combination, TenX ceased being a shell company. The material terms of the Business Combination are described in the section entitled “Proposal
No. 1 — The Business Combination Proposal” beginning on page 111 of the Final Prospectus, in the information set forth
under “Introductory Note” and in the information set forth under Item 2.01 in this Current Report on Form 8-K, each of which
is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(a) Financial statements of businesses acquired
The
unaudited financial statements of SpinCo as of and for the six months ended March 31, 2024 and 2023 are set forth in the Final Prospectus,
beginning on page F-37 and are incorporated herein by reference.. SpinCo’s audited financial statements are set forth
in the Final Prospectus beginning on page F-47 and are incorporated herein by reference.
(b) Pro Forma Financial Information
The
unaudited pro forma condensed combined financial information of the Company for the six months ended March 31, 2024 and the year
ended December 31, 2023 are set forth in the section entitled “Unaudited Pro Forma Condensed Combined Financial Information”
beginning on page 50 of the Final Prospectus and is herein by reference.
(d) Exhibits.
Exhibit
No. |
|
Document |
|
Filed
Herewith |
|
Form |
|
Exhibit |
|
Filing
Date |
2.1* |
|
Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. |
|
|
|
8-K |
|
2.1 |
|
10/24/2023 |
3.1 |
|
Certificate of Incorporation of Citius Oncology, Inc. |
|
X |
|
|
|
|
|
|
3.2 |
|
Bylaws of Citius Oncology, Inc. |
|
X |
|
|
|
|
|
|
4.1 |
|
Specimen Common Stock Certificate of Citius Oncology, Inc. |
|
|
|
S-4 |
|
4.5 |
|
07/11/2024 |
10.1 |
|
Amended and Restated Registration Rights Agreement, dated as of August 12, 2024 by and between Citius Oncology, Inc. and the signatories thereto. |
|
X |
|
|
|
|
|
|
10.2 |
|
Amended and Restated Shared Services Agreement, dated as of August 12, 2024, by and among Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. |
|
X |
|
|
|
|
|
|
10.3† |
|
2024 Omnibus Stock Incentive Plan. |
|
|
|
8-K |
|
10.5 |
|
8/5/2024 |
10.4* |
|
Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s Laboratories S.A. and Citius Pharmaceuticals, Inc. |
|
|
|
S-4 |
|
10.15 |
|
11/13/2023 |
10.5* |
|
Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. |
|
|
|
S-4 |
|
10.16 |
|
11/13/2023 |
10.6* |
|
Amendment No. 1 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. |
|
|
|
S-4 |
|
10.17 |
|
11/13/2023 |
10.7* |
|
Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. |
|
|
|
S-4 |
|
10.18 |
|
11/13/2023 |
10.8 |
|
Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. |
|
X |
|
|
|
|
|
|
10.9 |
|
Promissory Note, dated August 16, 2024, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. |
|
X |
|
|
|
|
|
|
16.1 |
|
Letter from Marcum LLP to the Securities and Exchange Commission, dated August 16, 2024. |
|
x |
|
|
|
|
|
|
21.1 |
|
Subsidiaries of Citius Oncology, Inc. |
|
X |
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
|
x |
|
|
|
|
|
|
| * | Certain of the exhibits
and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2) or 601(a)(5), as applicable. TenX agrees
to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. |
| † | Indicates management contract or compensatory plan. |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August 16, 2024
|
CITIUS ONCOLOGY, INC. |
|
|
|
|
By: |
/s/ Leonard Mazur |
|
Name: |
Leonard Mazur |
|
Title: |
Chief Executive Officer |
|
|
(Principal Executive Officer) |
14
Exhibit 3.1
CERTIFICATE OF INCORPORATION
OF
CITIUS Oncology, Inc.
August 5, 2024
The undersigned, for the purpose of forming a corporation
under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “DGCL”),
hereby certifies as follows:
I. NAME
The name of the corporation is Citius Oncology, Inc. (the “Company”).
II. REGISTERED OFFICE AND AGENT
The address of the Company’s registered office in the State of
Delaware is 3500 South DuPont Highway, in the City of Dover, Kent County, Delaware 19901. The name of its registered agent at such address
is Incorporating Services, Ltd.
III. PURPOSE
The purpose of the Company is to engage in any lawful act or activity
for which corporations may be organized under the DGCL.
IV. CAPITAL STOCK
| A. | The total number of shares of capital stock which may be issued by the Company is 110,000,000, of which
100,000,000 shares shall be common stock of the par value of $0.0001 per share (the “Common Stock”) and 10,000,000
shares shall be preferred stock of the par value of $0.0001 per share (the “Preferred Stock”). |
| B. | Each holder of Common Stock, as such, shall be entitled to one vote for each share of Common Stock held
of record by such holder on all matters on which stockholders generally are entitled to vote; provided, however, that, except as otherwise
required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate of Incorporation
(this “Certificate”) (including any Preferred Stock Designation (as hereinafter defined)) that relates solely
to the terms of one or more outstanding classes or series of Preferred Stock if the holders of such affected classes or series are entitled,
either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to this Certificate
(including any Preferred Stock Designation) or pursuant to the DGCL. |
| C. | The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or
resolutions providing for such issue duly adopted by the Board of Directors and by filing a certificate pursuant
to applicable law of the State of Delaware (hereinafter referred to as a “Preferred Stock Designation”) pursuant
to the DGCL; and in such resolution or resolutions and Preferred Stock Designation providing for the issue of shares of each particular
series, the Board of Directors is expressly authorized to fix the annual rate or rates of dividends for the particular series; the dividend
payment dates for the particular series and the date from which dividends on all shares of such series issued prior to the record date
for the first dividend payment date shall be cumulative; the redemption price or prices for the particular series; the voting powers for
the particular series; the rights, if any, of holders of the shares of the particular series to convert the same into shares of any other
series or class or other securities of the Company, with any provisions for the subsequent adjustment of such conversion rights; and to
classify or reclassify any unissued preferred shares by fixing or altering from time to time any of the foregoing rights, privileges and
qualifications. All shares of the Preferred Stock of any one series shall be identical with each other in all respects, except that shares
of any one series issued at different times may differ as to the dates from which dividends thereon shall be cumulative; and all shares
of Preferred Stock shall be of equal rank, regardless of series, and shall be identical in all respects except as to the particulars fixed
by the Board of Directors as hereinabove provided or as fixed herein. |
V. BOARD OF DIRECTORS
| A. | Except as otherwise provided by applicable law or this Certificate, the business and affairs of the Company
shall be managed by or under the direction of the Board of Directors. |
| B. | The total number of directors shall be as determined from time to time exclusively by the Board of Directors;
provided that, at any time Citius Pharmaceuticals, Inc. (together with its Affiliates (as defined below), subsidiaries, successors and
assigns (other than the Company and its subsidiaries), “Citius Pharmaceuticals, Inc.”) beneficially owns, in
the aggregate, at least 50% in voting power of the then-outstanding shares of stock of the Company entitled to vote generally in the election
of directors, the stockholders may also fix the number of directors by resolution adopted by the stockholders, in each case, subject to
the rights of any holders of Preferred Stock to elect directors pursuant to any Preferred Stock Designation. Election of directors need
not be by written ballot unless the bylaws of the Company (as the same may be amended and/or restated from time to time, the “Bylaws”)
shall so require. |
As used in this Certificate, the term
“Affiliate” means a Person that directly, or indirectly through one or more intermediaries, controls, is controlled
by, or is under common control with, another Person, except that, with respect to Citius Pharmaceuticals, Inc., the term “Affiliate”
shall not include (a) the Company, and (b) any entity that is controlled by the Company (including its direct and indirect subsidiaries).
As used in this Certificate, the term “Person” means any individual, corporation, general or limited partnership,
limited liability company, joint venture, trust, association or any other entity.
| C. | Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under
specified circumstances, the Board of Directors of the Company shall be divided into three classes designated
as Class I, Class II and Class III, respectively. The Board of Directors may assign members of the Board of Directors already in office
to such classes. To the extent practicable, the Board of Directors shall assign an equal number of directors to Class I, Class II and
Class III. At the first annual meeting of stockholders after the filing of this Certificate, the terms of the Class I directors shall
expire, and Class I directors shall be elected for a full term of office to expire at the third succeeding annual meeting of stockholders
after their election. At the second annual meeting of stockholders, the terms of the Class II directors shall expire, and Class II directors
shall be elected for a full term of office to expire at the third succeeding annual meeting of stockholders after their election. At the
third annual meeting of stockholders, the terms of the Class III directors shall expire, and Class III directors shall be elected for
a full term of office to expire at the third succeeding annual meeting of stockholders after their election. At each succeeding annual
meeting of stockholders, directors elected to succeed the directors of the class whose terms expire at such meeting shall be elected for
a full term of office to expire at the third succeeding annual meeting of stockholders after their election. If the number of directors
is changed, any increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as
nearly equal as practicable, and any additional director of any class elected to fill a vacancy resulting from an increase in such class
shall hold office for a term that shall coincide with the remaining term of that class. No decrease in the number of directors constituting
the Board of Directors shall shorten the term of any incumbent director. |
| D. | Except as otherwise required by law or this Certificate, any vacancy resulting from the death, resignation,
removal or disqualification of a director or other cause, or any newly created directorship in the Board of Directors, may be filled by
a majority of the directors then in office, although less than a quorum, by the sole remaining director, or by the stockholders of the
Company; provided, however, that from and after the Trigger Event (as defined below), any vacancy resulting from the death, resignation,
removal or disqualification of a director or other cause, or any newly created directorship in the Board of Directors, shall be filled
only by a majority of the directors then in office, although less than a quorum, or by the sole remaining director, and shall not be filled
by the stockholders of the Company, in each case, subject to the rights of the holders of any series of Preferred Stock. Except as otherwise
provided by this Certificate, a director elected to fill a vacancy or newly created directorship shall hold office until the annual meeting
of stockholders for the election of directors of the class to which he or she has been appointed and until his or her successor has been
duly elected and qualified, subject, however, to such director’s earlier death, resignation, retirement, removal or disqualification. |
For purposes of this Certificate, “Trigger
Event” means, following the receipt by Citius Pharmaceuticals, Inc. of the shares of Common Stock to which it is entitled
under that certain Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals,
Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc., the time that Citius Pharmaceuticals, Inc. and its Affiliates
first cease to beneficially own more than 50% in voting power of the then-outstanding shares of stock of the Company entitled to vote
generally in the election of directors.
| E. | Except as otherwise required by law or this Certificate, and subject to the rights of the holders of any
series of Preferred Stock, directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting
power of the then-outstanding shares of stock of the Company entitled to vote generally in the election of such directors; provided, however,
that, from and after the Trigger Event any such director or all such directors may be removed only for cause and only by the affirmative
vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of stock of the Company entitled to vote thereon,
voting together as a single class. |
VI. CONSENT OF STOCKHOLDERS IN LIEU OF MEETING;
SPECIAL MEETINGS OF
STOCKHOLDERS
| A. | Any action required or permitted to be taken by stockholders must be effected at a duly called annual
or special meeting of stockholders; provided, that prior to the Trigger Event, any action required or permitted to be taken
at any annual or special meeting of stockholders of the Company may be taken without a meeting, without prior notice and without a vote,
if a consent or consents, setting forth the action so taken, is signed by or on behalf of the holders of record of outstanding stock having
not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled
to vote thereon were present and voted, is delivered to the Company in accordance with the DGCL, in each case, subject to the rights of
the holders of any series of Preferred Stock with respect to such series of Preferred Stock. |
| | |
| B. | Special meetings of stockholders for the transaction of such business as may properly come before the
meeting may only be called by order of the Chairman of the Board of Directors, the Board of Directors (pursuant to a resolution adopted
by the affirmative vote of a majority of the authorized number of directors constituting the Board of Directors, whether or not there
exist any vacancies or other unfilled seats in previously authorized directorships) or the Chief Executive Officer of the Company; provided, however,
that at any time prior to the Trigger Event, special meetings of the stockholders of the Company for any purpose or purposes shall also
be called by or at the direction of the Board of Directors or the Chairman of the Board of Directors at the request of Citius Pharmaceuticals,
Inc., in each case, subject to the rights of the holders of any series of Preferred Stock with respect to such series of Preferred Stock.
Any such special meeting of stockholders shall be held at such date, time, and place, within or without the State of Delaware, as may
be specified by such order. The Board of Directors may, in its sole discretion, determine that special meetings of stockholders shall
not be held at any place but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the DGCL.
If such order fails to fix such place, the meeting shall be held at the principal executive offices of the Company. |
VII. LIMITATION OF LIABILITY
To the fullest
extent permitted by the DGCL as the same exists or as may hereafter be amended, no present or former director of the Company shall
be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director. Neither any
amendment nor repeal of this Article, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this
Article, shall eliminate or reduce the effect of this Article in respect of any matter occurring, or any cause of action, suit or
claim that, but for this Article, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent
provision.
VIII. CORPORATE OPPORTUNITIES AND COMPETITION
| A. | In recognition and anticipation that (i) certain directors, officers, principals, partners, members, managers,
employees, agents and/or other representatives of Citius Pharmaceuticals, Inc. and its Affiliates may serve as directors, officers or
agents of the Company and its Affiliates, and (ii) Citius Pharmaceuticals, Inc. and its Affiliates may now engage and may continue to
engage in the same or similar activities or related lines of business as those in which the Company and Affiliates, directly or indirectly,
may engage and/or other business activities that overlap with or compete with those in which the Company and its Affiliates, directly
or indirectly, may engage, the provisions of this Article VIII are set forth to regulate and define the conduct of certain affairs of
the Company and its Affiliates with respect to certain classes or categories of business opportunities as they may involve Citius Pharmaceuticals,
Inc. and its Affiliates and any person or entity who, while a stockholder, director, officer or agent of the Company or any of its Affiliates,
is a director, officer, principal, partner, member, manager, employee, agent and/or other representative of Citius Pharmaceuticals, Inc.
and its Affiliates (each, an “Identified Person”), on the one hand, and the powers, rights, duties and
liabilities of the Company and its Affiliates and its and their respective stockholders, directors, officers and agents in connection
therewith, on the other. |
| B. | To the fullest extent permitted by law (including, without limitation, the DGCL), and notwithstanding
any other duty (contractual, fiduciary or otherwise, whether at law or in equity), each Identified Person (i) shall have the right to,
and shall have no duty (contractual, fiduciary or otherwise, whether at law or in equity) not to, directly or indirectly engage in and
possess interests in other business ventures of every type and description, including those engaged in the same or similar business activities
or lines of business as the Company or any of its Affiliates or deemed to be competing with the Company or any of its Affiliates, on its
own account, or in partnership with, or as a direct or indirect equity holder, controlling person, stockholder, director, officer, employee,
agent, Affiliate (including any portfolio company), member, financing source, investor, director or indirect manager, general or limited
partner or assignee of any other person or entity with no obligation to offer to the Company or its subsidiaries or other Affiliates the
right to participate therein and (ii) shall have the right to invest in, or provide services to, any person that is engaged in the same
or similar business activities as the Company or its Affiliates or directly or indirectly competes with the Company or any of its Affiliates.
To the fullest extent permitted by applicable law, but subject to the immediately preceding sentence, neither the Company nor any of its
subsidiaries shall have any rights in any business interests, activities or ventures of any Identified Person, and the Company hereby
waives and renounces any interest or expectancy therein, except with respect to opportunities offered solely and expressly
to officers of the Company in their capacity as such. |
IX. EXCLUSIVE FORUM
| A. | Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction,
any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal
district court for the District of Delaware) and any appellate court therefrom, shall, to the fullest extent permitted by law, be the
sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim
of breach of a fiduciary duty owed by any current or former director, officer, employee or stockholder of the Company to the Company or
the Company’s stockholders, (iii) any action asserting a claim against the Company or any current or former director, officer, employee
or stockholder of the Company arising pursuant to any provision of the DGCL or of this Certificate or the Bylaws (as either may be amended
and/or restated from time to time), (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of
this Certificate or the Bylaws (each as may be amended from time to time, including any right, obligation or remedy thereunder), (v) any
action or proceeding asserting a claim against the Company or any current or former director, officer, employee or stockholder of the
Company as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi) any action asserting an “internal
corporate claim,” as that term is defined in Section 115 of the DGCL. This Article IX.A. shall not apply to claims arising under
the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. |
| B. | Unless the Company consents in writing to the selection of an alternative forum, to the fullest extent
permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933. |
| C. | Any person or entity purchasing or otherwise acquiring any interest in shares of stock of the Company
shall be deemed to have notice of and, to the fullest extent permitted by law, to have consented to the provisions of this Article IX. |
X. SECTION 203 OF THE DGCL
The Company hereby expressly elects not to be
governed by Section 203 of the DGCL until the occurrence of a Trigger Event; whereupon, the Company shall immediately and automatically,
without further action on the part of the Company or any holder of stock of the Company, become governed by Section 203 of the DGCL, except
that the restrictions on business combinations of Section 203 of the DGCL will not apply to Citius Pharmaceuticals, Inc. or its current
or future Affiliates regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of capital
stock of the Company entitled to vote generally in the election of directors beneficially owned by them.
XI. AMENDMENT OF CERTIFICATE OF INCORPORATION AND BYLAWS
| A. | The Company reserves the right to amend, alter, change or repeal any provision contained in this Certificate,
in the manner now or hereafter prescribed by this Certificate and the DGCL, and all rights, preferences and privileges herein conferred
upon stockholders by and pursuant to this Certificate in its current form or as hereafter amended are granted subject to the rights reserved
in this Article XI. Notwithstanding the foregoing, from and after the occurrence of the Trigger Event, notwithstanding any other provisions
of this Certificate or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any greater or additional
vote or consent required hereunder (including any vote of the holders of any particular class or classes or series of stock required by
law or by this Certificate or any Preferred Stock Designation), the affirmative vote of the holders of at least 66 2/3% of the voting
power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, shall be required to alter,
amend or repeal Articles V (Board of Directors), VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), VII
(Limitation of Liability), VIII (Corporate Opportunities and Competition), IX (Exclusive Forum), X (Section 203 of the DGCL) and this
Article XI, and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the circumvention
of the provisions set forth in any of such Articles. |
| B. | In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the
Board of Directors is expressly authorized to make, alter and repeal the Bylaws without the consent or vote of the stockholders in any
manner not inconsistent with the laws of the State of Delaware or this Certificate. Any adoption, amendment or repeal of the Bylaws of
the Company by the Board of Directors shall require the approval of a majority of the total authorized number of directors. From and after
the occurrence of the Trigger Event, notwithstanding any other provisions of this Certificate or any provision of law that might otherwise
permit a lesser vote or no vote, but in addition to any additional or greater vote or consent required hereunder (including any vote of
the holders of any particular class or classes or series of stock required by law or by this Certificate or any Preferred Stock Designation),
the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon,
voting together as a single class, shall be required in order for the stockholders of the Company to alter, amend or repeal, in whole
or in part, any provision of the Bylaws or to adopt any provision inconsistent therewith. |
XII. INCORPORATOR
The name and mailing address of the
incorporator is as follows:
Dahe Zhang
420 Lexington Avenue
Suite 2446
New York NY 10170
I, THE UNDERSIGNED, being the incorporator,
for the purpose of forming a corporation pursuant to the DGCL, do make this Certificate of Incorporation, hereby acknowledging, declaring,
and certifying that the foregoing Certificate of Incorporation is my act and deed and that the facts herein stated are true, and have
accordingly hereunto set my hand this 5th day of August 2024.
|
/s/ Dahe Zhang |
|
Dahe Zhang |
|
Sole Incorporator |
6
Exhibit 3.2
BYLAWS
OF
Citius
ONCOLOGY, INC.
I.
CORPORATE OFFICES
The registered office of Citius
Oncology, Inc. (the “Company”) in the State of Delaware shall be 3500 Dupont Hwy. City of Dover, County of Kent,
Delaware 19901. The name of the registered agent of the Company at such location is Incorporating Services, Ltd.
The Company may at any time
establish other offices at any place or places within or without the State of Delaware as the Board of Directors of the Company (the “Board”)
may from time to time determine, or as the affairs of the Company may require.
II.
MEETINGS OF STOCKHOLDERS
| 2.1 | Place of Meetings; Remote Communication Meetings |
All meetings of the stockholders
shall be held at such place, if any, either within or without the State of Delaware, as shall be designated from time to time by the Board
and stated in the notice of meeting. The Board may, in its sole discretion, determine that a meeting shall not be held at any place, but
may instead be held solely by means of remote communication as authorized by the Delaware General Corporate Law (“DGCL”).
If authorized by the Board
in its sole discretion, and subject to such guidelines and procedures as the Board may adopt, stockholders and proxyholders not physically
present at a meeting of stockholders may, by means of remote communication, participate in a meeting of stockholders, be deemed present
in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely by means of remote
communication, provided that (i) the Company shall implement reasonable measures to verify that each person deemed present and permitted
to vote at the meeting by means of remote communication is a stockholder or proxyholder; (ii) the Company shall implement reasonable measures
to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters submitted
to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings;
and (iii) if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a record of such
vote or other action shall be maintained by the Company.
The annual meeting of the
stockholders for the election of directors and for the transaction of such other business as may properly come before the meeting shall
be held at such date, time and place, if any, as shall be determined by the Board and stated in the notice of the meeting.
Special meetings of the stockholders
for any purpose or purposes may be called at any time by the chair of the Board or the president and may not be called by another person
or persons. The only business which may be conducted at a special meeting shall be the matter or matters set forth in the notice of such
meeting.
| 2.4 | Notice of Stockholders’ Meetings |
| A. | Notice of the place, if any, date, hour, the record date for determining the stockholders entitled to
vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting) and means of remote
communication, if any, of every meeting of stockholders shall be given by the Company in accordance with Section 2.5 of these bylaws not
less than ten (10) days nor more than sixty (60) days before the meeting (unless a different time is specified by law) to every stockholder
entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting. Notices of special
meetings shall also specify the purpose or purposes for which the meeting has been called. |
| B. | Without limiting the manner by which notice otherwise may be given effectively to stockholders, notice
of meetings may be given to stockholders by means of electronic transmission in accordance with applicable law. |
| C. | Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice
to stockholders given by the Company shall be effective if given by a single written notice to stockholders who share an address if consented
to by the stockholders at that address to whom such notice is given. Any such consent shall be revocable by the stockholder by written
notice to the Company. Any stockholder who fails to object in writing to the Company, within sixty (60) days of having been given written
notice by the Company of its intention to send the single notice permitted under this Section 2.4(C), shall be deemed to have consented
to receiving such single written notice. |
| 2.5 | Manner of Giving Notice; Affidavit of Notice |
| A. | Written notice of any meeting of stockholders, if mailed, is given when deposited in the United States
mail, postage prepaid, directed to the stockholder at the stockholder’s address as it appears on the records of the Company. An
affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the Company that the notice has been given
shall, in the absence of fraud, be prima facie evidence of the facts stated therein. |
| B. | Notice given pursuant to this Section 2.5(B) shall be deemed given: (i) if by facsimile telecommunication,
when directed to a number at which the stockholder has consented to receive notice; (ii) if by electronic
mail, when directed to an electronic mail address at which the stockholder has consented to receive notice in writing or by course of
conduct; (iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon
the later of such posting and the giving of such separate notice; and (iv) if by any other form of electronic transmission, when directed
to the stockholder. An affidavit of the secretary, an assistant secretary or the transfer agent or other agent of the Company that the
notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated
therein. |
| A. | The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in
person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as
otherwise provided by statute or by the Certificate of Incorporation. If, however, such quorum is not present or represented at any meeting
of the stockholders, then the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power, by the
affirmative vote of a majority in voting power thereof, to adjourn the meeting from time to time, without notice other than announcement
at the meeting, until a quorum is present or represented. A quorum, once established, shall not be broken by the subsequent withdrawal
of enough votes to leave less than a quorum. At such adjourned meeting at which a quorum is present or represented, any business may be
transacted that might have been transacted at the meeting as originally noticed. |
| B. | Where a separate vote by a class or series or classes or series is required, a majority of the outstanding
shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to
take action with respect to that vote on that matter and, in all matters other than the election of directors, the affirmative vote of
the majority of shares of such class or series or classes or series present in person or represented by proxy at the meeting shall be
the act of such class or series or classes or series. |
The chair of any meeting of
stockholders, whether annual or special may in his or her discretion adjourn for any reason from time to time to reconvene at the same
or some other place, if any, and notice need not be given of any such adjourned meeting if the new time, place, if any, thereof and the
means of remote communication by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, if
any, are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Company may transact any business that
might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, or if after the adjournment
a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled
to vote at the meeting. If after the adjournment a new record date is fixed for stockholders and proxyholders entitled to vote at the
adjourned meeting, the Board shall fix a new record date for notice of the adjourned meeting and shall give notice of the adjourned meeting
to each stockholder of record and proxyholder entitled to vote at
the adjourned meeting as of the record date fixed for notice of the adjourned meeting.
Any previously scheduled annual
or special meeting of the stockholders may be postponed or adjourned, and any previously scheduled annual or special meeting of the stockholders
may be canceled, by resolution of the Board; provided, however, that with respect to any special meeting of stockholders previously scheduled
by the Board or the Chair of the Board of Directors at the request of Citius Pharmaceuticals, Inc. (as defined in the Certificate of Incorporation),
the Board shall not postpone, reschedule or cancel such special meeting without the prior written consent of Citius Pharmaceuticals, Inc.
| A. | The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with
the provisions of Section 2.11 of these bylaws, subject to the provisions of Section 217 and 218 of the DGCL. |
| B. | Except as otherwise provided in the Certificate of Incorporation, each stockholder shall be entitled to
one vote, in person or by proxy, for each share of capital stock held by such stockholder. |
| C. | Unless otherwise required by law or the Certificate of Incorporation, the election of directors shall
be decided by a plurality of the votes cast at a meeting of the stockholders by the holders of stock entitled to vote in the election.
Unless otherwise required by law or the Certificate of Incorporation, an amendment to the Certificate of Incorporation to effect a reverse
stock split or increase or reduce the number of authorized shares of a class of capital stock shall be decided by a majority of votes
cast on the matter at a meeting of the stockholders. Unless otherwise required by law, the Certificate of Incorporation or these bylaws,
any matter, other than the election of directors, brought before any meeting of stockholders shall be decided by the affirmative vote
of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the matter. Voting at meetings
of stockholders need not be by written ballot. |
Whenever notice is required
to be given under any provision of the DGCL or of the Certificate of Incorporation or these bylaws, a written waiver thereof, signed by
the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after such notice
is required, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting,
except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of
any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any
regular or special meeting of the stockholders need be specified in any written waiver or any waiver by electronic transmission of notice
unless so required by the Certificate of Incorporation or these bylaws.
| 2.10 | Stockholder Action by Written Consent Without a Meeting |
Except as otherwise provided in the Certificate
of Incorporation, any action required or permitted to be taken by the stockholders of the Company must be taken at an annual or special
meeting of the stockholders of the Company and may not be effected by any consent in writing by the stockholders.
| 2.11 | Record Date for Stockholder Notice; Voting; Giving Consents |
In order that the Company
may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled
to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of
any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date
that shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting, nor more than sixty (60) days prior
to any other action, provide that a record date may not precede the date upon which the resolution citing the record date is adopted by
the Board.
If the Board does not so fix
a record date:
| A. | the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders
shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of
business on the day next preceding the day on which the meeting is held; |
| B. | the record date for determining stockholders entitled to express consent to corporate action in writing
without a meeting, when no prior action by the Board is necessary, shall be the day on which the first written consent is expressed; and |
| C. | the record date for determining stockholders for any other purpose shall be at the close of business on
the day on which the Board adopts the resolution relating thereto. |
A determination of stockholders
of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however,
that the Board may fix a new record date for the adjourned meeting and in such case shall also fix as the record date for stockholders
entitled to notice of such adjourned meeting the same or an earlier date as that fixed for the determination of stockholders entitled
to vote therewith at the adjourned meeting.
Each stockholder entitled
to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another
person or persons to act for such stockholder by a written proxy, signed by the stockholder and filed with the secretary of the Company,
but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A proxy
shall be deemed signed if the stockholder’s name is placed on the proxy (whether by manual signature, typewriting, telegraphic transmission
or otherwise) by the stockholder or the stockholder’s attorney-in-fact. The revocability of a proxy that states on its face
that it is irrevocable shall be governed by the provisions of Section 212(e) of the DGCL.
| 2.13 | List of Stockholders Entitled to Vote |
The officer of the Company
who has charge of the stock ledger of the Company shall prepare and make, at least ten (10) days before every meeting of stockholders,
a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder
and the number of shares registered in the name of each stockholder. The Company shall not be required to include electronic mail addresses
or other electronic contact information on such list. Such list shall be open to the examination of any stockholder for any purpose germane
to the meeting for a period of at least ten (10) days prior to the meeting: (a) on a reasonably accessible electronic network, provided
that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business
hours, at the principal place of business of the Company. In the event that the Company determines to make the list available on an electronic
network, the Company may take reasonable steps to ensure that such information is available only to stockholders of the Company. If the
meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time
thereof, and may be examined by any stockholder who is present. If the meeting is to be held solely by means of remote communication,
then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible
electronic network, and the information required to access such list shall be provided with the notice of the meeting. Except as provided
by applicable law, the stock ledger of the Company shall be the only evidence as to who are the stockholders entitled to examine the stock
ledger and the list of stockholders or to vote in person or by proxy at any meeting of stockholders.
| 2.14 | Stockholder Proposals |
| A. | Effective upon the Company’s initial public offering of stock under the Securities Act of 1933,
as amended, any stockholder wishing to bring any other business before a meeting of stockholders, including, but not limited to, the nomination
of persons for election as directors, must provide notice to the Company not more than one hundred and twenty (120) and not less than
ninety (90) days before the meeting in writing by registered mail, return receipt requested, of the business to be presented by the stockholders
at the stockholders’ meeting. Any such notice shall set forth the following as to each matter the stockholder proposes to bring
before the meeting: (i) a brief description of the business desired to be brought before the meeting and the reasons for conducting such
business at the meeting and, if such business includes a proposal to amend the bylaws of the Company, the language of the proposed amendment;
(ii) the name and address, as they appear on the Company’s books, of the stockholder proposing such business; (iii) a representation
that the stockholder is a holder of record of stock of the Company entitled to vote at such meeting and intends to appear in person or
by proxy at the meeting to propose such business; and (iv) any material interest of the stockholder in such business and any Stockholder
Associated Person (as defined below), individually or in the aggregate, including any anticipated benefit to the stockholder or the Stockholder
Associated Person therefrom. |
| B. | For the purposes of these bylaws, “Stockholder Associated Person” of any stockholder
means (i) any person controlling, either directly or indirectly, or acting in concert with, such stockholder; (ii) any beneficial owner
of shares of stock of the Company owned of record or beneficially by such stockholder; and (iii) any person controlling, controlled by
or under common control with such Stockholder Associated Person. |
| C. | As to the stockholder giving notice and any Stockholder Associated Person, any such notice shall also
set forth the (i) class, series and number of all shares beneficially owned by such stockholder and by such Stockholder Associated Person;
(ii) the nominee holder for, and number of shares owned beneficially, but not of record by such stockholder and by any such Stockholder
Associated Person; and (iii) whether and the extent to which any hedging or other transaction or series of transactions has been entered
into by or on behalf of, or any other agreement, arrangement or understanding (including any short position or any borrowing or lending
of shares) has been made, the effect or intent of which is to mitigate loss to or manage risk or benefit of share price changes for, or
to increase or decrease the voting power of, such stockholder of any such Stockholder Associated Person with respect to any share of stock
of the Company. Notwithstanding the foregoing provisions of this Section 2.14, a stockholder shall also comply with all applicable requirements
of all applicable laws, rules and regulations, including, but not limited to, the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder, with respect to the matters set forth in this Section 2.14. In the absence of such notice to the meeting
the above requirements, a stockholder shall not be entitled to present any business at any meeting of stockholders. |
| 2.15 | Inspectors of Meetings of Stockholders |
The Board, in advance of
any meeting of stockholders, may, and shall if required by law, appoint one or more inspectors, who may be employees of the Company,
to act at the meeting or any adjournment thereof and make a written report thereof. The Board may designate one or more persons as alternate
inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting, the person presiding
at the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of the
inspector’s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according
to the best of the inspector’s ability. The inspectors shall: (a) ascertain the number of shares outstanding and the voting power
of each; (b) determine the shares represented at the meeting, the existence of a quorum and the validity of proxies and ballots; (c)
count all votes and ballots; (d) determine and retain for a reasonable period a record of the disposition of any challenges made to any
determination by the inspectors; and (e) certify their determination of the number of shares represented at the meeting and their count
of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance
of their duties. Unless otherwise provided by the Board, the date and time of the opening and the closing of the polls for each matter
upon which the stockholders will vote at a meeting shall be announced at the meeting. No ballot, proxies, votes or any revocation thereof
or change thereto, shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery of the State of Delaware
upon application by a stockholder shall determine otherwise. In determining the validity and counting of proxies and ballots cast at
any meeting of stockholders, the inspectors may consider such information as is permitted by applicable law. No person who is a candidate
for office at an election may serve as an inspector at such election.
III.
DIRECTORS
Subject to the provisions
of the DGCL and any limitations in the Certificate of Incorporation or these bylaws relating to action required to be approved by the
stockholders or by the outstanding shares, the business and affairs of the Company shall be managed and all corporate powers shall be
exercised by or under the direction of the Board. The Board may adopt such rules and procedures, not inconsistent with the Certificate
of Incorporation, these bylaws or applicable law, as it may deem proper for the conduct of its meetings and the management of the Company.
Subject to the Certificate
of Incorporation, the Board shall consist of one or more members, the number thereof to be determined from time to time by resolution
of the Board. The directors shall be divided into classes as and to the extent provided in the Certificate of Incorporation, except as
otherwise required by applicable law. Each director shall hold office until a successor is duly elected and qualified or until the director’s
earlier death, resignation, disqualification or removal.
No reduction of the authorized
number of directors shall have the effect of removing any director before that director’s term of office expires.
| 3.3 | Election, Qualification and Term of Office of Directors |
Subject to the Certificate
of Incorporation, and except as provided in Sections 3.4 and 3.16 of these bylaws, directors shall be elected at each annual
meeting of stockholders to hold office until the next election of the class for which such director shall have been chosen. Directors
need not be stockholders unless so required by the Certificate of Incorporation or these bylaws, wherein other qualifications for directors
may be prescribed. Each director, including a director elected or appointed to fill a vacancy, shall hold office until such director’s
successor is elected and qualified or until such director’s earlier resignation or removal. Each director shall be a natural person.
Elections of directors need
not be by written ballot.
| 3.4 | Resignation and Vacancies |
Any director may resign at
any time upon notice given in writing or electronic transmission to the Company. Such resignation shall take effect at the date of receipt
of such notice by the Company or at such later time as is therein specified. Vacancies occurring in any directorship for any reason shall
be filled in accordance with the Certificate of Incorporation.
Unless otherwise provided
in the Certificate of Incorporation or these bylaws, whenever the holders of any class or classes of stock or series thereof are entitled
to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such
class or classes or series may be filled by a majority of the directors elected by such class or classes or series thereof then in office,
or by a sole remaining director so elected.
| 3.5 | Place of Meetings; Remote Communication Meetings |
The Board may hold meetings,
both regular and special, either within or outside the State of Delaware.
Unless otherwise restricted
by the Certificate of Incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in
a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons
participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.
Regular meetings of the Board
may be held without notice at such time and at such place as shall from time to time be determined by the Board.
| 3.7 | Special Meetings; Notice |
Special meetings of the Board
for any purpose or purposes may be called at any time by the chair of the Board or the president. Notice of the time and place of special
meetings shall be delivered either personally or by mail, facsimile, telephone or electronic transmission to each director, addressed
to each director at such director’s address and/or phone number and/or electronic transmission address as it is shown on the records
of the Company. If the notice is mailed, it shall be deposited in the United States mail at least four (4) days before the time of the
holding of the meeting. If the notice is delivered personally or by facsimile, telephone or other electronic transmission, it shall be
delivered by telephone or transmitted at least forty-eight (48) hours before the time of the holding of the meeting. Any oral notice given
personally or by telephone may be communicated either to the director or to a person at the office of the director who the person giving
the notice has reason to believe will promptly communicate it to the director. The notice need not specify the purpose or the place of
the meeting if the meeting is to be held at the principal executive office of the Company. Notice may be delivered by any person entitled
to call a special meeting or by an agent of such person.
At all meetings of the Board,
a majority of the authorized number of directors shall constitute a quorum for the transaction of business and the act of a majority of
the directors present at any meeting at which there is a quorum shall be the act of the Board, except as otherwise specifically provided
by statute or by the Certificate of Incorporation. If a quorum is not present at any meeting of the Board, then the directors present
thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.
Whenever notice to directors
is required to be given under any provision of the DGCL, the Certificate of Incorporation or these bylaws, a written waiver thereof, signed
by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the
time stated therein, shall be deemed equivalent to notice. Attendance by a director at a meeting shall constitute a waiver of notice of
such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction
of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of,
any regular or special meeting of the directors, or meeting of a committee of directors, need be specified in any written waiver of notice
unless so required by the Certificate of Incorporation or these bylaws.
A majority of the directors
present at any meeting of the Board, including an adjourned meeting, whether or not a quorum is present, may adjourn and reconvene such
meeting to another time and place. At least forty-eight (48) hours’ notice of any adjourned meeting of the Board shall be given
to each director whether or not present at the time of the adjournment, if such notice shall be given by electronic means, or at least
three (3) days’ notice if by mail. Any business may be transacted at an adjourned meeting that might have been transacted at the
meeting as originally called.
| 3.11 | Board Action by Written Consent Without a Meeting |
Unless otherwise restricted
by the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any
committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing
or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings
of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form
if the minutes are maintained in electronic form.
| 3.12 | Fees and Compensation of Directors |
Unless otherwise restricted
by the Certificate of Incorporation or these bylaws, the Board shall have the authority to fix the compensation of directors.
Unless otherwise restricted
by statute, by the Certificate of Incorporation or by these bylaws, any director or the entire Board may be removed, with or without cause,
by the holders of a majority of the shares then entitled to vote at an election of directors; provided, that, whenever the holders of
any class or classes of stock, or series thereof, are entitled to elect one or more directors by the provisions of the Certificate of
Incorporation, removal of any directors elected by such class or classes of stock, or series thereof, shall be by the holders of a majority
of the shares of such class or classes of stock, or series of stock, then entitled to vote at an election of directors.
| 3.14 | Chair of the Board of Directors |
The Company may also have,
at the discretion of the Board, a chair of the Board. The chair of the Board shall, if such a person is elected, preside at the meetings
of the Board and exercise and perform such other powers and duties as may from time to time be assigned to such chair by the Board, or
as may be prescribed in Section 5.6 herein or as otherwise prescribed by these bylaws.
| 3.15 | Nominating Procedures |
Nominations for the election
of directors may only be made by the Board, by the nominating committee of the Board (or, if none, any other committee serving a similar
function) or by any stockholder entitled to vote generally in elections of directors where the stockholder complies with the requirements
of this Section 3.15. Any stockholder of record entitled to vote generally in elections of directors may nominate one or more persons
for election as directors at a meeting of stockholders only if written notice of such stockholder’s intent to make such nomination
or nominations has been given, either by personal delivery or by United States certified mail, postage prepaid, to the secretary of the
Company (i) with respect to an election to be held at an annual meeting of stockholders, not more than one hundred and twenty (120) days
nor less than ninety (90) days in advance of such meeting, and (ii) with respect to an election to be held at a special meeting of stockholders
called for the purpose of the election of directors, not later than the close of business on the tenth (10th) business day following the
date on which notice of such meeting is first given to stockholders. Each such notice of a stockholder’s intent to nominate a director
or directors at an annual or special meeting shall set forth the following: (A) the name and address, as they appear on the Company’s
books, of the stockholder who intends to make the nomination and the name and residence address of the person or persons to be nominated;
(B) the class and number of shares of the Company which are beneficially owned by the stockholder; (C) a representation that the stockholder
is a holder of record of stock of the Company entitled to vote at such meeting and intends to appear in person or by proxy at the meeting
to nominate the person or persons specified in the notice; (D) a description of all arrangements or understandings between the stockholder
and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to
be made by the stockholder; (E) such other information regarding each nominee proposed by such stockholder as would be required to be
disclosed in solicitations of proxies for election of directors, or as would otherwise be required, in each case pursuant to Regulation
14A under the Securities Exchange Act of 1934, as amended, including any information that would be required to be included in a proxy
statement filed pursuant to Regulation 14A had the nominee been nominated by the Board; and (F) the written consent of each nominee to
be named in a proxy statement and to serve as director of the Company if so elected. If the chair of the stockholders’ meeting shall
determine that a nomination was not made in accordance with the procedures described by these bylaws, he or she shall so declare to the
meeting, and the defective nomination shall be disregarded. Notwithstanding the foregoing provisions of this Section, a stockholder shall
also comply with all applicable requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder with respect to the matters set forth in this Section.
IV.
COMMITTEES OF BOARD OF DIRECTORS
| 4.1 | Committees of Directors |
The Board may, by resolution
passed by a majority of the whole Board, designate one or more committees, with each committee to consist of one or more of the directors
of the Company. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified
member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present
at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another
member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided
in the resolution of the Board or in the bylaws of the Company, shall have and may exercise all the powers and authority of the Board
in the management of the business and affairs of the Company, and may authorize the seal of the Company to be affixed to all papers that
may require it; but no such committee shall have the power or authority to (i) approve or adopt, or recommend to the stockholders, any
action or matter expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any bylaws
of the Company.
Each committee shall keep
regular minutes of its meetings and report the same to the Board when required.
| 4.3 | Meetings and Actions of Committees |
Meetings and actions of committees
shall be governed by, and be held and taken in accordance with, the provisions of Article III of these bylaws, Section 3.5 (Place
of Meetings and Meetings by Telephone), Section 3.6 (Regular Meetings), Section 3.7 (Special Meetings and Notice), Section
3.8 (Quorum), Section 3.9 (Waiver of Notice), Section 3.10 (Adjourned Meeting and Notice), and Section 3.11 (Board
Action by Written Consent Without a Meeting), with such changes in the context of those bylaws as are necessary to substitute the committee
and its members for the Board and its members; provided, however, that the time of regular meetings of committees may also be called by
resolution of the Board and that notice of special meetings of committees shall also be given to all alternate members, who shall have
the right to attend all meetings of the committee. The Board may adopt rules for the government of any committee not inconsistent with
the provisions of these bylaws.
V.
OFFICERS
The officers of the Company
shall be a chief executive officer, a president, a secretary and a treasurer. The Company may also have, at the discretion of the Board,
a chair of the Board, one or more vice presidents, assistant secretaries, assistant treasurers and any such other officers as may be appointed
in accordance with the provisions of Section 5.3 of these bylaws. Any number of offices may be held by the same person.
The officers of the Company,
except such officers as may be appointed in accordance with the provisions of Section 5.3 of these bylaws, shall be chosen by the Board,
subject to the rights, if any, of an officer under any contract of employment.
The Board may appoint, or
empower the president to appoint, such other officers and agents as the business of the Company may require, each of whom shall hold office
for such period, have such authority and perform such duties as are provided in these bylaws or as the Board may from time to time determine.
| 5.4 | Removal and Resignation of Officers |
Subject to the rights, if
any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by an affirmative vote
of the majority of the Board at any regular or special meeting of the Board or by any officer upon whom such power of removal may be conferred
by the Board.
Any officer may resign at
any time upon notice given in writing or electronic transmission to the Company. Any resignation shall take effect at the date of the
receipt of that notice or at any later time specified in that notice; and, unless otherwise specified in that notice, the acceptance of
the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Company
under any contract to which the officer is a party.
Any vacancy occurring in any
office of the Company shall be filled by the Board.
| 5.6 | Chair of the Board of Directors |
The chair of the Board, if
such an officer be elected, shall, if present, preside at meetings of the Board and exercise and perform such other powers and duties
as may from time to time be assigned to the chair by the Board or as may be prescribed by these bylaws. If there is no chief executive
officer, then the chair of the Board shall also be the chief executive officer of the Company and shall have the powers and duties prescribed
in Section 5.7 of these bylaws. The chair of the board shall be chosen by the Board.
| 5.7 | Chief Executive Officer |
Subject to such supervisory
powers, if any, as may be given by the Board to the chair of the Board, the chief executive officer of the Company shall, subject to the
control of the Board, have general supervision, direction and control of the business and the officers of the Company. The chief executive
officer shall preside at all meetings of the stockholders and, in the absence or nonexistence of a chair of the B, at all meetings of
the Board at which he or she is present. The chief executive officer shall have the general powers and duties of management usually vested
in the office of chief executive officer of a company
and shall have such other powers and duties as may be prescribed by the Board or these bylaws.
Subject to such supervisory
powers, if any, as may be given by the Board to the chair of the Board or the chief executive officer, if there be such officers, the
president shall, subject to the control of the Board, have general supervision, direction and control of the business and the officers
of the Company. In the absence or nonexistence of the chief executive officer, he or she shall preside at all meetings of the stockholders
and, in the absence or nonexistence of a chair of the Board and chief executive officer, at all meetings of the Board at which he or she
is present. He or she shall have the general powers and duties of management usually vested in the office of president of a company and
shall have such other powers and duties as may be prescribed by the Board or these bylaws. The Board may provide in its discretion that
the offices of president and chief executive officer may be held by the same person.
In the absence or disability
of the chief executive officer and president, the vice presidents, if any, in order of their rank as fixed by the Board or, if not ranked,
a vice president designated by the Board, shall perform all the duties of the president and when so acting shall have all the powers of,
and be subject to all the restrictions upon, the president. The vice presidents shall have such other powers and perform such other duties
as from time to time may be prescribed for them by the Board, these bylaws, the president or the chair of the Board.
The treasurer shall keep and
maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of the properties and business transactions
of the Company, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings and
shares. The books of account shall at all reasonable times be open to inspection by any director.
The treasurer shall deposit
all money and other valuables in the name and to the credit of the Company with such depositaries as may be designated by the Board. The
treasurer shall disburse the funds of the Company as may be ordered by the Board, shall render to the president and directors, whenever
they request it, an account of all of the treasurer’s transactions as treasurer and of the financial condition of the Company, and
shall have such other powers and perform such other duties as may be prescribed by the Board or these bylaws.
The secretary or an agent
of the Company shall keep or cause to be kept, at the principal executive office of the Company or such other place as the Board may direct,
a book of minutes of all meetings and actions of directors, committees of directors and stockholders. The minutes shall show the time
and place of each meeting, whether regular or special (and, if special, how authorized and the notice given), the names of those present
at directors’ meetings or committee meetings, the number of shares present or represented
at stockholders’ meetings and the proceedings thereof.
The secretary shall keep,
or cause to be kept, at the principal executive office of the Company or at the office of the Company’s transfer agent or registrar,
as determined by resolution of the Board, a share register, or a duplicate share register, showing the names of all stockholders and their
addresses, the number and classes of shares held by each, the number and date of certificates evidencing such shares, and the number and
date of cancellation of every certificate surrendered for cancellation.
The secretary shall give,
or cause to be given, notice of all meetings of the stockholders and of the Board required to be given by law or by these bylaws. The
secretary shall keep the seal of the Company, if one be adopted, in safe custody and shall have such other powers and perform such other
duties as may be prescribed by the Board or by these bylaws.
The assistant secretary, or,
if there is more than one, the assistant secretaries in the order determined by the stockholders or the Board (or if there be no such
determination, then in the order of their election) shall, in the absence of the secretary or in the event of the secretary’s inability
or refusal to act, perform the duties and exercise the powers of the secretary and shall perform such other duties and have such other
powers as the Board of Directors or the stockholders may from time to time prescribe.
| 5.13 | Representation of Shares of Other Corporations |
The chair of the Board, the
chief executive officer, the president, any vice president, the treasurer, the secretary or assistant secretary of the Company, or any
other person authorized by the Board of Directors or the chief executive officer, president or a vice president, is authorized to vote,
represent, and exercise on behalf of the Company all rights incident to any and all shares of any other corporation or corporations standing
in the name of the Company. The authority granted herein may be exercised either by such person directly or by any other person authorized
to do so by proxy or power of attorney duly executed by such person having the authority.
| 5.14 | Authority and Duties of Officers |
In addition to the foregoing
authority and duties, all officers of the Company shall respectively have such authority and perform such duties in the management of
the business of the Company as may be designated from time to time by the Board or the stockholders.
Officers
of the Company shall be entitled to such salaries, compensation or reimbursement as shall be fixed or allowed from time to time by the
Board.
VI.
Indemnification
| 6.1 | Indemnification Respecting Third Party Claims |
The Company, to the full
extent and in a manner permitted by the DGCL as in effect from time to time, shall indemnify, in accordance with the provisions of this
Article, any person (including the heirs, executors, administrators or estate of any such person) who was or is made a party to or is
threatened to be made a party to any threatened, pending or completed action, suit or proceeding (including any appeal thereof), whether
civil, criminal, administrative, or investigative (other than an action by or in the right of the Company or by any corporation, limited
liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which the Company owns, directly or
indirectly through one or more other entities, a majority of the voting power or otherwise possesses a similar degree of control), by
reason of the fact that such person is or was a director, officer, employee or agent of the Company, or is or was serving at the request
of the Company as a director, officer, member, manager, partner, trustee, fiduciary, employee or agent (a “Subsidiary Officer”)
of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise (any
such entity for which a Subsidiary Officer so serves, an “Associated Entity”), against expenses, including
attorneys’ fees and disbursements, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person
in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed
to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe his conduct was unlawful; provided, however, that (i) the Company shall not be obligated to indemnify a person
who is or was a director, officer employee or agent of the Company or a Subsidiary Officer of an Associated Entity against expenses incurred
in connection with an action, suit, proceeding or investigation to which such person is threatened to be made a party but does not become
a party unless the incurring of such expenses was authorized by or under the authority of the Board of Directors and (ii) the Company
shall not be obligated to indemnify against any amount paid in settlement unless the Board of Directors has consented to such settlement.
The termination of any action, suit or proceeding by judgment, order, settlement or conviction or upon a plea of nolo contendere
or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person
reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding,
that such person had reasonable cause to believe that his conduct was unlawful. Notwithstanding anything to the contrary in the foregoing
provisions of this Section 6.1, a person shall not be entitled, as a matter of right, to indemnification pursuant to this Section
6.1 against costs or expenses incurred in connection with any action, suit or proceeding commenced by such person against the Company
or any Associated Entity or any person who is or was a director, officer, fiduciary, employee or agent of the Company or a Subsidiary
Officer of any Associated Entity (including, without limitation, any action, suit or proceeding commenced by such person to enforce such
person’s rights under this Article, unless and only to the extent that such person is successful on the merits of such claim),
but such indemnification may be provided by the Company in a specific case as permitted by Section 6.7 of this Article VI.
| 6.2 | Indemnification Respecting Derivative Claims |
The Company, to the full extent
and in a manner permitted by the DGCL as in effect from time to time, shall indemnify, in accordance with the provisions of this Article,
any person (including the heirs, executors, administrators or estate of any such person) who was or is made a party to or is threatened
to be made a party to any threatened, pending or completed action or suit (including any appeal thereof) brought in the right of the Company
to procure a judgment in its favor by reason of the fact that such person is or was a director, officer, employee or agent of the Company,
or is or was serving at the request of the Company as a Subsidiary Officer of an Associated Entity, against expenses (including attorneys’
fees and disbursements) and costs actually and reasonably incurred by such person in connection with the defense or settlement of such
action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best
interests of the Company, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person
shall have been adjudged to be liable to the Company unless, and only to the extent that, the Delaware Court of Chancery or the
court in which such action or suit was brought shall determine that, despite the adjudication of liability but in view of all the circumstances
of the case, such person is fairly and reasonably entitled to indemnity for such expenses and costs as the Court of Chancery or such other
court shall deem proper; provided, however, that the Company shall not be obligated to indemnify a director, officer, employee
or agent of the Company or a Subsidiary Officer of an Associated Entity against expenses incurred in connection with an action or suit
to which such person is threatened to be made a party but does not become a party unless the incurrence of such expenses was authorized
by or under the authority of the Board of Directors. Notwithstanding anything to the contrary in the foregoing provisions of this Section
6.2, a person shall not be entitled, as a matter of right, to indemnification pursuant to this Section 6.2 against costs and
expenses incurred in connection with any action or suit in the right of the Company commenced by such person, but such indemnification
may be provided by the Company in any specific case as permitted by Section 6.7 in this Article VI.
| 6.3 | Determination of Entitlement to Indemnification |
Any indemnification to be
provided under either of Section 6.1 or 6.2 above in this Article (unless ordered by a court of competent jurisdiction
or advanced as provided in Section 6.5 of this Article) shall be made by the Company only as authorized in the specific case upon
a determination that indemnification is proper under the circumstances because the person to be indemnified had met the applicable standard
of conduct set forth in such section of this Article. Such determination shall be made, with respect to a person who is a director or
officer of the Company at the time of such determination, (i) by a majority vote of the directors who are not parties to the action,
suit or proceeding in respect of which indemnification is sought, even though less than a quorum, or (ii) by majority vote of the members
of a committee composed of at least two directors each of whom is not a party to such action, suit or proceeding, designated by majority
vote of directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (iii) if there are no directors
who are not parties to such action, suit or proceeding, or if such directors so direct, by independent legal counsel in a written opinion,
or (iv) by action of the stockholders taken as permitted by law and these Bylaws. Such determination shall be made, with respect to any
other person, by such officer or officers of the Company as the Board of Directors may designate, in accordance with any procedures that
the Board of Directors or such designated officer or officers may determine, or, if any such officer or officers have not been so designated,
by the Chief Legal Officer or the General Counsel of the Company. In the event a request for indemnification is made by any person referred
to in Section 6.1 or 6.2 above in this Article, the Company shall use its reasonable best efforts to cause such determination
to be made not later than sixty (60) days after such request is made after the final disposition of such action, suit or proceeding.
| 6.4 | Right to Indemnification upon Successful Defense and for
Service as a Witness |
| A. | Notwithstanding the other provisions of this Article, to the extent that a present or former director
or officer has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in either of Section
6.1 or 6.2 above in this Article, or in defense of any claim, issue or matter therein, such person shall be indemnified against
expenses (including attorneys’ fees and disbursements) and costs actually and reasonably incurred by such person in connection therewith. |
| B. | To the extent any person who is or was a director, officer, employee or agent of the Company or a Subsidiary
Officer of an Associated Entity has served or prepared to serve as a witness in, but is not a party to, any action, suit or proceeding
(whether civil, criminal, administrative, regulatory or investigative in nature), including any investigation by any legislative or regulatory
body or by any securities or commodities exchange of which the Company or an Associated Entity is a member or to the jurisdiction of which
it is subject, by reason of his or her services as a director, officer, employee or agent of the Company, or his or her service as a Subsidiary
Officer of an Associated Entity (assuming such person is or was serving at the request of the Company as a Subsidiary Officer of such
Associated Entity), the Company may indemnify such person against expenses (including attorneys’ fees and disbursements) and out-of-pocket
costs actually and reasonably incurred by such person in connection therewith and, if the Company has determined to so indemnify such
person, shall use its reasonable best efforts to provide such indemnity within sixty (60) days after receipt by the Company from such
person of a statement requesting such indemnification, averring such service and reasonably evidencing such expenses and costs; it being
understood, however, that the Company shall have no obligation under this Article to compensate such person for such person’s time
or efforts so expended. |
| A. | Expenses and costs incurred by any present or former director or officer of the Company in defending a
civil, criminal, administrative, regulatory or investigative action, suit or proceeding shall, to the extent permitted by law, be paid
by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking in writing by or
on behalf of such person to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified
in respect of such costs and expenses by the Company as authorized by this Article. |
| B. | Expenses and costs incurred by any other person referred to in Section 6.1 or 6.2 above
in this Article in defending a civil, criminal, administrative, regulatory or investigative action, suit or proceeding may be paid by
the Company in advance of the final disposition of such action, suit or proceeding as authorized by or under the authority of the Board
of Directors upon receipt of an undertaking in writing by or on behalf of such person to repay such amount if it shall ultimately be determined
that such person is not entitled to be indemnified by the Company in respect of such costs and expenses as authorized by this Article
and subject to any limitations or qualifications provided by or under the authority of the Board of Directors. |
| 6.6 | Notice of Action; Assumption of the Defense |
Promptly after receipt by
any person referred to in Section 6.1, 6.2 or 6.5 of this Article of notice of the commencement of any action, suit
or proceeding in respect of which indemnification or advancement of expenses may be sought under any such Section, such person (the “Indemnitee”)
shall notify the Company thereof. The Company shall be entitled to participate in the defense of any such action, suit or proceeding and,
to the extent that it may wish, except in the case of a criminal action or proceeding, to assume the defense thereof with counsel chosen
by it. If the Company shall have notified the Indemnitee of its election so to assume the defense, it shall be a condition of any further
obligation of the Company under such Sections to indemnify the Indemnitee with respect to such action, suit or proceeding that the Indemnitee
shall have provided an undertaking in writing to repay all legal or other costs and expenses subsequently incurred by the Company in conducting
such defense if it shall ultimately be determined that the Indemnitee is not entitled to be indemnified in respect of the costs and expenses
of such action, suit or proceeding by the Company as authorized by this Article. Notwithstanding anything in this Article to the contrary,
after the Company shall have notified the Indemnitee of its election so to assume the defense, the Company shall not be liable under such
Sections for any legal or other costs or expenses subsequently incurred by the Indemnitee in connection with the defense of such action,
suit or proceeding, unless (a) the parties thereto include both (i) the Company and the Indemnitee, or (ii) the Indemnitee and other persons
who may be entitled to seek indemnification or advancement of expenses under any such Section and with respect to whom the Company shall
have elected to assume the defense, and (b) the counsel chosen by the Company to conduct the defense shall have determined, in their sole
discretion, that, under applicable standards of professional conduct, a conflict of interest exists that would prevent them from representing
both (i) the Company and the Indemnitee, or (ii) the Indemnitee and such other persons, as the case may be, in which case the Indemnitee
may retain separate counsel at the expense of the Company to the extent provided in such sections and Section 6.3 in this Article.
| 6.7 | Indemnification Not Exclusive |
The provision of indemnification
to or the advancement of expenses and costs to any person under this Article, or the entitlement of any person to indemnification or advancement
of expenses and costs under this Article, shall not limit or restrict in any way the power of the Company to indemnify or advance expenses
and costs to such person in any other way permitted by law or be deemed exclusive of, or invalidate, any right to which any person seeking
indemnification or advancement of expenses and costs may be entitled under any law, agreement, vote of stockholders or disinterested directors
or otherwise, both as to action in such person’s capacity as an officer, director, employee or
agent of the Company or a Subsidiary Officer of an Associated Entity and as to action in any other capacity.
| 6.8 | Corporate Obligations; Reliance |
The provisions of Sections
6.1, 6.2, 6.4(a) and 6.5(a) of this Article shall be deemed to create a binding obligation on the part of the
Company to the directors, officers, employees and agents of the Company, and the persons who are serving at the request of the Company
as Subsidiary Officers of Associated Entities, on the effective date of this Article and persons thereafter elected as directors and officers
or retained as employees or agents, or serving at the request of the Company as Subsidiary Officers of Associated Entities (including
persons who served as directors, officers, employees and agents, or served at the request of the Company as Subsidiary Officers of Associated
Entities, on or after such date but who are no longer so serving at the time they present claims for advancement of expenses or indemnity),
and such persons in acting in their capacities as directors, officers, employees or agents of the Company, or serving at the request of
the Company as Subsidiary Officers of any Associated Entity, shall be entitled to rely on such provisions of this Article.
Neither the amendment nor
repeal of this Article, nor the adoption of any provision of the Certificate of Incorporation inconsistent with this Article, shall eliminate
or reduce the effect of such provisions in respect of any act or omission or any matter occurring prior to such amendment, repeal or adoption
of an inconsistent provision regardless of when any cause of action, suit or claim relating to any such matter accrued or matured or was
commenced, and such provision shall continue to have effect in respect of such act, omission or matter as if such provision had not been
so amended or repealed or if a provision inconsistent therewith had not been so adopted.
The right, if any, of any
person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a Subsidiary
Officer of an Associated Entity, to indemnification or advancement of expenses under Sections 6.1 through 6.9 in this Article
shall continue after he or she shall have ceased to be a director, officer, employee or agent or a Subsidiary Officer of an Associated
Entity and shall inure to the benefit of the heirs, distributees, executors, administrators and other legal representatives of such person.
The Company may purchase and
maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at
the request of the Company as a Subsidiary Officer of any Associated Entity, against any liability asserted against such person and incurred
by such person in any such capacity, or arising out of such person’s status as such, whether or not the Company would have the power
to indemnify such person against such liability under the provisions of this Article or applicable law.
| 6.12 | Definitions of Certain Terms |
For purposes of this Article,
references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit
plan; references to “serving at the request of the Company” shall include any service as a director, officer
employee or agent of the Company or as a Subsidiary Officer of any Associated Entity which service imposes duties on, or involves services
by, such person with respect to any employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and
in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall
be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this
Article.
VII.
RECORDS AND REPORTS
| 7.1 | Maintenance and Inspection of Records |
| A. | The Company shall, either at its principal executive office or at such place or places as designated by
the Board, keep a record of its stockholders listing their names and addresses and the number and class of shares held by each stockholder,
a copy of these bylaws as amended to date, accounting books and other records. |
| B. | Any stockholder of record, in person or by attorney or other agent, shall, upon written demand under oath
stating the purpose thereof and subject to execution of a confidentiality agreement, have the right during the usual hours for business
to inspect for any proper purpose the Company’s stock ledger, a list of its stockholders and its other books and records and to
make copies or extracts therefrom. A proper purpose shall mean a purpose reasonably related to such person’s interest as a stockholder.
In every instance where an attorney or other agent is the person who seeks the right to inspection, the demand under oath shall be accompanied
by a power of attorney or such other writing that authorizes the attorney or other agent to so act on behalf of the stockholder. The demand
under oath shall be directed to the Company at its registered office in Delaware or at its principal place of business. |
| C. | Any records maintained by a corporation in the regular course of its business, including its stock ledger,
books of account and minute books, may be kept on, or by means of, or be in the form of, any information storage device or method, provided
that the records so kept can be converted into clearly legible paper form within a reasonable time. Any corporation shall so convert any
records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the Certificate of Incorporation,
these bylaws or the DGCL. When records are kept in such manner, a clearly legible paper form from or by means of the information storage
device or method shall be admissible in evidence, and accepted for all other purposes, to the same extent as an original paper record
of the same information would have been, provided the paper form accurately portrays the record. |
| 7.2 | Inspection by Directors |
Any director shall have
the right to examine the Company’s stock ledger, a list of its stockholders and its other books and records for a purpose
reasonably related to the director’s position as a director. The Court of Chancery is hereby vested with the exclusive
jurisdiction to determine whether a director is entitled to the inspection sought. The court may summarily order the Company to
permit the director to inspect any and all books and records, the stock ledger and the stock list and to make copies or extracts
therefrom. The burden of proof shall be upon the Company to establish that the inspection such director seeks is for an improper
purpose. The court may, in its discretion, prescribe any limitations or conditions with reference to the inspection, or award such
other and further relief as the court may deem just and proper.
VIII.
STOCK CERTIFICATES AND THEIR TRANSFER
| 8.1 | Certificates Representing Shares |
The shares of stock of the
Company shall be represented by certificates, unless the Board provides by resolution or resolutions that some or all of any class or
series shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock. CARTA or
another electronic stock certificate system may be used for issuing stock certificates and serving as the stock ledger. If shares are
represented by certificates, such certificates shall be in the form, other than bearer form, approved by the Board. The certificates representing
shares of stock of each class shall be signed by, or in the name of, the Company, by the chair, any vice chair, the president or any vice
president, and by the secretary, any assistant secretary, the treasurer or any assistant treasurer. Any or all such signatures may be
facsimiles. The signatures on a certificate may be the signatures of the same person, so long as
each signature is made in a separate officer capacity of such person. Although any officer, transfer agent or registrar whose manual
or facsimile signature is affixed to such a certificate ceases to be such officer, transfer agent or registrar before such certificate
has been issued, it may nevertheless be issued by the Company with the same effect as if such officer, transfer agent or registrar were
still such at the date of its issue. The Company shall not have power to issue a certificate in bearer form.
Stock of the Company shall
be transferable in the manner prescribed by law and in these bylaws. Transfers of stock shall be made on the books of the Company only
by the holder of record thereof, by such person’s attorney lawfully constituted in writing and, in the case of certificated shares,
upon the surrender of the certificate thereof, which shall be cancelled before a new certificate or uncertificated shares shall be issued.
No transfer of stock shall be valid as against the Company for any purpose until it shall have been entered in the stock records of the
Company by an entry showing from and to whom transferred. To the extent designated by the president or any vice president or the treasurer
of the Company, the Company may recognize the transfer of fractional uncertificated shares, but shall not otherwise be required to recognize
the transfer of fractional shares.
| 8.3 | Transfer Agents and Registrars |
The Board may appoint, or
authorize any officer or officers to appoint, one or more transfer agents and one or more registrars.
| 8.4 | Lost, Stolen or Destroyed Certificates |
The Company may direct a new
certificate or uncertificated shares to be issued in place of any certificate theretofore issued by the Company alleged to have been lost,
stolen or destroyed upon the making of an affidavit of that fact by the owner of the allegedly lost, stolen or destroyed certificate.
When authorizing such issue of a new certificate or uncertificated shares, the Board may, in its discretion and as a condition precedent
to the issuance thereof, require the owner of the lost, stolen or destroyed certificate, or the owner’s legal representative to
give the Company a bond sufficient to indemnify it against any claim that may be made against the Company with respect to the certificate
alleged to have been lost, stolen or destroyed or the issuance of such new certificate or uncertificated shares.
IX.
GENERAL MATTERS
From time to time, the Board
shall determine by resolution which person or persons may sign or endorse all checks, drafts, other orders for payment of money, notes
or other evidences of indebtedness that are issued in the name of or payable to the Company, and only the persons so authorized shall
sign or endorse those instruments.
| 9.2 | Execution of Corporate Contracts and Instruments |
The Board, except as otherwise
provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument
in the name of and on behalf of the Company; such authority may be general or confined to specific instances. Unless so authorized or
ratified by the Board or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind
the Company by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
The fiscal year of the Company
shall be fixed by resolution of the Board and may be changed by the Board.
The Company may adopt a corporate
seal which may be altered as desired, and may use the same by causing it, or a facsimile thereof, to be impressed or affixed or in any
other manner reproduced.
| A. | The directors of the Company, subject to any rights or restrictions contained in the Certificate of Incorporation,
may declare and pay dividends upon the shares of its capital stock pursuant to the DGCL. Dividends may be paid in cash, in property or
in shares of the Company’s capital stock. |
| B. | The directors of the Company may set apart out of any of the funds of the Company available for dividends
a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing
dividends, repairing or maintaining any property of the Company and meeting contingencies. |
| 9.6 | Electronic Transmission |
For purposes of these bylaws,
“electronic transmission” means any form of communication, not directly involving the physical transmission
of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced
in paper form by such a recipient through an automated process.
| 9.7 | Construction; Definitions |
Unless the context requires
otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the construction of these bylaws. Without
limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, reference
to gender is not limiting, and the term “person” includes both an entity and a natural person.
| 9.8 | Stock Transfer Agreements and Restrictions |
The Company shall have power
to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Company to restrict
the transfer of shares of stock of the Company of any one or more classes owned by such stockholders in any manner not prohibited by the
DGCL.
| 9.9 | Special Designation on Certificates |
If the Company is authorized
to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences, and the
relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations
or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that
the Company shall issue to represent such class or series of stock; provided, however, that, except as otherwise provided in Section 202
of the DGCL, in lieu of the foregoing requirements there may be set forth on the face or back of the certificate that the Company shall
issue to represent such class or series of stock a statement that the Company will furnish without charge to each stockholder who so requests
the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock
or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
| 9.10 | Conflict With Applicable Law or Certificate of Incorporation |
These bylaws are adopted subject
to any applicable law and the Certificate of Incorporation. Whenever these bylaws may conflict with any applicable law or the Certificate
of Incorporation, such conflict shall be resolved in favor of such law or the Certificate of Incorporation.
Any records maintained by
the Company in the regular course of its business, including its stock ledger, books of account and minute books, may be maintained on
any information storage device or by any method; provided that the records so kept can be converted into clearly legible paper form within
a reasonable time. The Company shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant
to applicable law.
X.
AMENDMENTS
These bylaws may be amended,
altered, changed, adopted and repealed or new bylaws adopted by the Board in any manner not inconsistent with the DGCL or the Certificate
of Incorporation. From and after the occurrence of the Trigger Event (as defined in the Certificate of Incorporation), notwithstanding
any other provisions of these Bylaws or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to
any additional or greater vote or consent required by the Certificate of Incorporation (including any vote of the holders of any particular
class or classes or series of stock required by law or by the Certificate of Incorporation), the affirmative vote of the holders of at
least 66 2/3% of the voting power of the outstanding shares of stock entitled to vote thereon, voting together as a single class, shall
be required in order for the stockholders of the Company to alter, amend or repeal, in whole or in part, any provision of these Bylaws
or to adopt any provision inconsistent herewith.
25
Exhibit 10.1
EXECUTION VERSION
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT
THIS AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 9, 2024, is made and entered into by and
among (i) Citius Oncology, Inc., a Delaware corporation, formerly known as TenX Keane Acquisition, a Cayman Islands exempted company (the
“Company”), (ii) the equityholders designated as Sponsor Equityholders on the signature page hereto (collectively,
the “Sponsor Equityholders”); and (iii) Citius Pharmaceuticals, Inc. (the “Legacy Citius Oncology
Equityholder” and, together with the Sponsor Equityholders and any person or entity who hereafter becomes a party to this
Agreement pursuant to Section 6.2 of this Agreement, the “Holders” and individually, a “Holder”).
Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to such terms in the Merger Agreement
(as defined below).
RECITALS
WHEREAS, the Company
and the Sponsor Equityholders are parties to that certain Registration Rights Agreement, dated as of October 13, 2022 (the “Prior
Agreement”);
WHEREAS, the Company,
TenX Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Citius Oncology Sub, Inc., an entity formerly
known as Citius Oncology, Inc., a Delaware corporation (“Legacy Citius Oncology”), are parties to that certain
Agreement and Plan of Merger, dated as of October 23, 2023 (as amended or restated from time to time, the “Merger Agreement”),
pursuant to which, on the date hereof, Merger Sub merged (the “Merger”) with and into Legacy Citius Oncology,
with Legacy Citius Oncology surviving the Merger as a wholly owned subsidiary of the Company;
WHEREAS, the Legacy
Citius Oncology Equityholder is receiving shares of common stock, par value $0.0001 per share, of the Company (the “Common
Stock”) on or about the date hereof, pursuant to the Merger Agreement (the “Merger Shares”);
WHEREAS, in connection
with the consummation of the Merger, the parties to the Prior Agreement desire to amend and restate the Prior Agreement in its entirety
as set forth herein, and the parties hereto desire to enter into this Agreement pursuant to which the Company shall grant the Holders
certain registration rights with respect to the Registrable Securities (as defined below) on the terms and conditions set forth in this
Agreement, effective as of the Closing; and
WHEREAS, pursuant
to Section 5.5 of the Prior Agreement, no amendment, modification or termination of the Prior Agreement shall be binding
upon any party unless executed in writing by such party.
NOW, THEREFORE,
in consideration of the representations, covenants and agreements contained herein, and certain other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
ARTICLE I
DEFINITIONS
1.1 Definitions.
Terms used, but not otherwise defined, shall have the meaning ascribed to them in the Merger Agreement. The terms defined in this Article
I shall, for all purposes of this Agreement, have the respective meanings set forth below:
“Adverse Disclosure”
shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the Chief Executive
Officer or Chief Financial Officer of the Company, after consultation with counsel to the Company, (i) would be required to be made in
any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus
and any preliminary prospectus, in the light of the circumstances under which they were made) not misleading, (ii) would not be required
to be made at such time if the Registration Statement were not being filed, declared effective or used, as the case may be, and (iii)
the Company has a bona fide business purpose for not making such information public.
“Agreement”
shall have the meaning given in the Preamble.
“Block Trade”
shall mean an offering and/or sale of Registrable Securities by any Holder on a block trade or underwritten basis (whether firm commitment
or otherwise) without substantial marketing efforts prior to pricing, including, without limitation, a same day trade, overnight trade
or similar transaction.
“Board”
shall mean the Board of Directors of the Company.
“Change
in Control” shall mean any transfer (whether by tender offer, merger, stock purchase, consolidation or other similar transaction),
in one transaction or a series of related transactions, to a person or group of affiliated persons of the Company’s voting securities
if, after such transfer, such person or group of affiliated persons would hold more than 50% of outstanding voting securities of the Company
(or surviving entity) or would otherwise have the power to control the Board or to direct the operations of the Company.
“Code”
shall have the meaning given in subsection 4.2.13.
“Commission”
shall mean the Securities and Exchange Commission.
“Common Stock”
shall have the meaning given in the Recitals.
“Company”
shall have the meaning given in the Preamble.
“Demand Registration”
shall have the meaning given in subsection 2.1.1.
“Demanding Holder”
shall have the meaning given in subsection 2.1.1.
“EDGAR”
shall have the meaning given in subsection 3.1.3.
“Exchange Act”
shall mean the Securities Exchange Act of 1934, as it may be amended from time to time.
“Form S-1”
shall have the meaning given in subsection 2.1.1.
“Form S-3”
shall have the meaning given in subsection 2.3.
“Founder Shares”
shall mean the 1,650,000 shares of ordinary shares of the Company, which subsequently converted into 1,650,000 shares of Common Stock,
issued to its initial stockholders prior to the Company’s initial public offering.
“Holder Information”
shall have the meaning given in subsection 5.1.2.
“Holders”
shall have the meaning given in the Preamble, for so long as such person or entity holds any Registrable Securities.
“Legacy Citius
Oncology” shall have the meaning given in the Recitals.
“Lock-up”
shall have the meaning given in Section 4.1.
“Lock-up Party”
shall have the meaning given in Section 4.1.
“Lock-up Period”
shall have the meaning given in Section 4.1.
“Maximum Number
of Securities” shall have the meaning given in subsection 2.1.4.
“Merger”
shall have the meaning given in the Recitals.
“Merger Agreement”
shall have the meaning given in the Recitals.
“Merger Shares”
shall have the meaning given in the Recitals.
“Merger Sub”
shall have the meaning given in the Recitals.
“Misstatement”
shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus (in the case of a Prospectus, in the light
of the circumstances under which they were made) not misleading.
“Permitted Transferees”
shall mean a person or entity to whom a Holder of Registrable Securities is permitted to transfer such Registrable Securities prior to
the expiration of the Lock-up Period under this Agreement, and any other applicable agreement between such Holder and the Company, and
to any transferee thereafter.
“Piggyback Registration”
shall have the meaning given in subsection 2.2.1.
“Prior Agreement”
shall have the meaning given in the Recitals.
“Private Placement
Rights” shall mean the 394,000 rights to receive two-tenths (2/10) of one ordinary share issued by the Company that were
part of the Private Placement Units which (i) subsequently converted into a right to receive two-tenths (2/10) of a share of Common Stock
in connection with the Domestication and in accordance with the Merger Agreement and (ii) were automatically converted into whole shares
of Common Stock at the Closing.
“Private Placement
Shares” shall mean the 394,000 ordinary shares issued by the Company as part of the Private Placement Units and which subsequently
converted into 394,000 shares of Common Stock in connection with the Domestication.
“Private Placement
Units” shall mean the 394,000 units issued by the Company that were privately purchased simultaneously with the consummation
of the Company’s initial public offering and for which each unit was comprised of one Private Placement Share and one Private Placement
Right.
“Pro Rata”
shall have the meaning given in subsection 2.1.4.
“Prospectus”
shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended
by any and all post-effective amendments and including all material incorporated by reference in such prospectus.
“Registrable
Security” shall mean (a) the Merger Shares, (b) the Founder Shares, (c) the shares of Common Stock issued upon the
conversion of the Private Placement Rights at the Closing,2 (d) the Private Placement Shares, (e) any outstanding Common
Stock or any other equity security (including the shares of Common Stock issued or issuable upon the exercise of any other equity security)
of the Company held by a Holder as of the date of this Agreement, (f) any equity securities (including the Common Stock issued or issuable
upon the exercise of any such equity security) of the Company issuable upon conversion of any working capital loans in an amount up to
$1,500,000 made to the Company by a Holder, and (g) any other equity security of the Company issued or issuable with respect to any such
Common Stock by way of a share dividend or share split or in connection with a combination of shares, recapitalization, merger, consolidation
or reorganization; provided, however, that, as to any particular Registrable Security, such securities shall cease
to be Registrable Securities upon the earliest to occur of: (A) a Registration Statement with respect to the sale of such securities shall
have become effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance
with such Registration Statement; (B) such securities shall have been otherwise transferred (other than to a Permitted Transferee), new
certificates for such securities not bearing (or book entry positions not subject to) a legend restricting further transfer shall have
been delivered by the Company and subsequent public distribution of such securities shall not require registration under the Securities
Act; (C) such securities shall have ceased to be outstanding; (D) such securities may be sold without registration pursuant to Rule 144
promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission) (but with no volume or other restrictions
or limitations); or (E) such securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other
public securities transaction.
“Registration”
shall mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements
of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming effective.
“Registration
Expenses” shall mean the out-of-pocket expenses of a Registration, including, without limitation, the following:
(A) all registration and
filing fees (including fees with respect to filings required to be made with the Financial Industry Regulatory Authority, Inc.) and any
securities exchange on which the Common Stock is then listed;
(B) fees and expenses of
compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the Underwriters in connection
with blue sky qualifications of Registrable Securities);
(C) printing, messenger,
telephone and delivery expenses;
(D) reasonable fees and disbursements
of counsel for the Company;
(E) reasonable fees and disbursements
of all independent registered public accountants of the Company incurred specifically in connection with such Registration; and
(F) in an Underwritten Offering,
reasonable fees and expenses of one (1) legal counsel selected by the majority-in-interest of the Demanding Holders (not to exceed $50,000
without prior written consent of the Company).
“Registration
Statement” shall mean any registration statement filed by the Company with the Commission that covers the Registrable Securities
pursuant to the provisions of this Agreement, including the Prospectus included in such registration statement, amendments (including
post-effective amendments) and supplements to such registration statement, and all exhibits to and all material incorporated by reference
in such registration statement.
“Regulations”
shall have the meaning given in subsection 4.2.13.
“Requesting Holder”
shall have the meaning given in subsection 2.1.1.
“Securities Act”
shall mean the Securities Act of 1933, as amended from time to time.
“Shelf”
shall mean the Form S-1 Shelf, the Form S-3 Shelf or any subsequent Shelf Registration.
“Shelf Registration”
shall mean a shelf registration of securities pursuant to a Registration Statement on Form S-1 or Form S-3 filed with the Commission in
accordance with and pursuant to Rule 415 promulgated under the Securities Act (or any successor rule then in effect).
“Sponsor Equityholders”
shall have the meaning given in the Preamble.
“Transfer”
shall mean the (a) the sale or assignment of, offer to sell, contract or agreement to sell, grant of any option to purchase or otherwise
dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation
with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Exchange Act with respect to, any security,
(b) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) public announcement
of any intention to effect any transaction specified in clause (a) or (b).
“Underwriter”
shall mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such
dealer’s market-making activities.
“Underwritten
Registration” or “Underwritten Offering” shall mean a Registration in which securities of the
Company are sold to an Underwriter in a firm commitment underwriting for distribution to the public.
ARTICLE II
REGISTRATIONS
2.1 Demand Registration.
2.1.1 Request for
Registration. Subject to the provisions of subsection 2.1.4 and Section 2.4 hereof, the Holders
of at least a majority in interest of the then-outstanding number of Registrable Securities (the “Demanding Holders”)
may make a written demand for Registration under the Securities Act of all or part of their Registrable Securities, which written demand
shall describe the amount and type of securities to be included in such Registration and the intended method(s) of distribution thereof
(such written demand a “Demand Registration”). The Company shall, within ten (10) days of the Company’s
receipt of the Demand Registration, notify, in writing, all other Holders of Registrable Securities of such demand, and each Holder of
Registrable Securities who thereafter wishes to include all or a portion of such Holder’s Registrable Securities in a Registration
pursuant to a Demand Registration (each such Holder that includes all or a portion of such Holder’s Registrable Securities in such
Registration, a “Requesting Holder”) shall so notify the Company, in writing, within five (5) days after the
receipt by the Holder of the notice from the Company. Upon receipt by the Company of any such written notification from a Requesting Holder(s)
to the Company, such Requesting Holder(s) shall be entitled to have their Registrable Securities included in a Registration pursuant to
a Demand Registration and the Company shall effect, as soon thereafter as practicable, but not more than sixty (60) days immediately after
the Company’s receipt of the Demand Registration, the Registration of all Registrable Securities requested by the Demanding Holders
and Requesting Holders pursuant to such Demand Registration.
2.1.2 Effective Registration.
Notwithstanding the provisions of subsection 2.1.1 above or any other part of this Agreement, a Registration pursuant
to a Demand Registration shall not count as a Registration unless and until (i) the Registration Statement filed with the Commission with
respect to a Registration pursuant to a Demand Registration has been declared effective by the Commission and (ii) the Company has complied
with all of its obligations under this Agreement with respect thereto; provided, further, that if, within six
months after such Registration Statement has been declared effective, an offering of Registrable Securities in a Registration pursuant
to a Demand Registration is subsequently interfered with by any stop order or injunction of the Commission, federal or state court or
any other governmental agency the Registration Statement with respect to such Registration shall be deemed not to have been declared effective,
unless and until, (i) such stop order or injunction is removed, rescinded or otherwise terminated, and (ii) a majority-in-interest of
the Demanding Holders initiating such Demand Registration thereafter affirmatively elect to continue with such Registration and accordingly
notify the Company in writing, but in no event later than five (5) days, of such election; and provided, further,
that the Company shall not be obligated or required to file another Registration Statement until the Registration Statement that has been
previously filed with respect to a Registration pursuant to a Demand Registration becomes effective or is subsequently terminated.
2.1.3 Underwritten
Offering. Subject to the provisions of subsection 2.1.4 and Section 2.4 hereof, if a majority-in-interest
of the Demanding Holders so advise the Company as part of their Demand Registration that the offering of the Registrable Securities pursuant
to such Demand Registration shall be in the form of an Underwritten Offering, then the right of such Demanding Holder or Requesting Holder
(if any) to include its Registrable Securities in such Registration shall be conditioned upon such Holder’s participation in such
Underwritten Offering and the inclusion of such Holder’s Registrable Securities in such Underwritten Offering to the extent provided
herein. All such Holders proposing to distribute their Registrable Securities through an Underwritten Offering under this subsection
2.1.3 shall enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering
by the majority-in-interest of the Demanding Holders initiating the Demand Registration.
2.1.4 Reduction of
Underwritten Offering. If the managing Underwriter or Underwriters in an Underwritten Registration pursuant to a Demand Registration,
in good faith, advises the Company, the Demanding Holders and the Requesting Holders (if any) in writing that the dollar amount or number
of Registrable Securities that the Demanding Holders and the Requesting Holders (if any) desire to sell, taken together with all other
shares of Common Stock or other equity securities that the Company desires to sell and shares of Common Stock, if any, as to which a Registration
has been requested pursuant to separate written contractual piggy-back registration rights held by any other stockholders who desire to
sell, exceeds the maximum dollar amount or maximum number of equity securities that can be sold in the Underwritten Offering without adversely
affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering (such maximum
dollar amount or maximum number of such securities, as applicable, the “Maximum Number of Securities”), then
the Company shall include in such Underwritten Offering, as follows: (i) first, the Registrable Securities of the Demanding Holders and
the Requesting Holders (if any) (pro rata based on the respective number of Registrable Securities that each Demanding Holder and Requesting
Holder (if any) has requested be included in such Underwritten Registration and the aggregate number of Registrable Securities that the
Demanding Holders and Requesting Holders have requested be included in such Underwritten Registration (such proportion is referred to
herein as “Pro Rata”)) that can be sold without exceeding the Maximum Number of Securities; (ii) second, to
the extent that the Maximum Number of Securities has not been reached under the foregoing clause (i), the Registrable Securities of Holders
(Pro Rata, based on the respective number of Registrable Securities that each Holder has so requested) exercising their rights to register
their Registrable Securities pursuant to subsection 2.2.1 hereof, without exceeding the Maximum Number of Securities;
(iii) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i) and (ii), the shares
of Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of
Securities; and (iv) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i),
(ii) and (iii), the Common Stock or other equity securities of other persons or entities that the Company is obligated to register in
a Registration pursuant to separate written contractual arrangements with such persons and that can be sold without exceeding the Maximum
Number of Securities.
2.1.5 Demand Registration
Withdrawal. A majority-in-interest of the Demanding Holders initiating a Demand Registration or a majority-in-interest of the Requesting
Holders (if any), pursuant to a Registration under subsection 2.1.1 shall have the right to withdraw from a Registration
pursuant to such Demand Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters
(if any) of their intention to withdraw from such Registration prior to the effectiveness of the Registration Statement filed with the
Commission with respect to the Registration of their Registrable Securities pursuant to such Demand Registration. Notwithstanding anything
to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with a Registration
pursuant to a Demand Registration as provided in Section 3.3 prior to its withdrawal under this subsection 2.1.5.
If withdrawn, a Demand Registration shall constitute a demand for an Underwritten Offering by the withdrawing Demanding Holder for purposes
of Section 2.1.1.
2.2 Piggyback Registration.
2.2.1 Piggyback Rights.
If the Company proposes to file a Registration Statement under the Securities Act with respect to an offering of equity securities, or
securities or other obligations exercisable or exchangeable for, or convertible into equity securities, for its own account or for the
account of stockholders of the Company (or by the Company and by the stockholders of the Company including, without limitation, pursuant
to Section 2.1 hereof), other than a Registration Statement (i) filed in connection with any employee stock option or
other benefit plan, (ii) for an exchange offer or offering of securities solely to the Company’s existing stockholders, (iii) for
an offering of debt that is convertible into equity securities of the Company, (iv) pursuant to a Registration Statement on Form S-4 (or
similar form that relates to a transaction subject to Rule 145 under the Securities Act or any successor rule thereto), (v) for a dividend
reinvestment plan, or (vi) for a Block Trade, then the Company shall give written notice of such proposed filing to all of the Holders
of Registrable Securities as soon as practicable but not less than ten (10) days before the anticipated filing date of such Registration
Statement or, in the case of an Underwritten Offering pursuant to a Shelf Registration, the applicable “red herring” prospectus
or prospectus supplement used for marketing such offering, which notice shall (A) describe the amount and type of securities to be included
in such offering, the intended method(s) of distribution, and the name of the proposed managing Underwriter or Underwriters, if any, in
such offering, and (B) offer to all of the Holders of Registrable Securities the opportunity to register the sale of such number of Registrable
Securities as such Holders may request in writing within five (5) days after receipt of such written notice (such Registration a “Piggyback
Registration”). Subject to Section 2.2.2, the Company shall, in good faith, cause such Registrable Securities
to be included in such Piggyback Registration and, if applicable, shall use its commercially reasonable efforts to cause the managing
Underwriter or Underwriters of a proposed Underwritten Offering to permit the Registrable Securities requested by the Holders pursuant
to this subsection 2.2.1 to be included in a Piggyback Registration on the same terms and conditions as any similar securities
of the Company included in such Registration and to permit the sale or other disposition of such Registrable Securities in accordance
with the intended method(s) of distribution thereof. All such Holders proposing to distribute their Registrable Securities through an
Underwritten Offering under this subsection 2.2.1 shall enter into an underwriting agreement in customary form with the
Underwriter(s) selected for such Underwritten Offering by the Company.
2.2.2 Reduction of
Piggyback Registration. If the managing Underwriter or Underwriters in an Underwritten Registration that is to be a Piggyback Registration,
in good faith, advises the Company and the Holders of Registrable Securities participating in the Piggyback Registration in writing that
the dollar amount or number of the shares of Common Stock or other equity securities that the Company desires to sell, taken together
with (i) the shares of Common Stock or other equity securities, if any, as to which Registration has been demanded pursuant to separate
written contractual arrangements with persons or entities other than the Holders of Registrable Securities hereunder, (ii) the Registrable
Securities as to which registration has been requested pursuant to Section 2.2 hereof, and (iii) the shares of Common
Stock or other equity securities, if any, as to which Registration has been requested pursuant to separate written contractual piggy-back
registration rights of other stockholders of the Company, exceeds the Maximum Number of Securities, then:
(a) If the Registration is undertaken
for the Company’s account, the Company shall include in any such Registration (A) first, the shares of Common Stock or other equity
securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; (B) second, to the
extent that the Maximum Number of Securities has not been reached under the foregoing clause (A), the Registrable Securities of Holders
exercising their rights to register their Registrable Securities pursuant to subsection 2.2.1 hereof, Pro Rata, which
can be sold without exceeding the Maximum Number of Securities; and (C) third, to the extent that the Maximum Number of Securities has
not been reached under the foregoing clauses (A) and (B), the shares of Common Stock or other equity securities, if any, as to which Registration
has been requested pursuant to written contractual piggy-back registration rights of other stockholders of the Company, which can be sold
without exceeding the Maximum Number of Securities;
(b) If the Registration is pursuant
to a request by persons or entities other than the Holders of Registrable Securities, then the Company shall include in any such Registration
(A) first, the shares of Common Stock or other equity securities, if any, of such requesting persons or entities, other than the Holders
of Registrable Securities, which can be sold without exceeding the Maximum Number of Securities; (B) second, to the extent that the Maximum
Number of Securities has not been reached under the foregoing clause (A), the Registrable Securities of Holders exercising their rights
to register their Registrable Securities pursuant to subsection 2.2.1, pro rata based on the number of Registrable Securities
that each Holder has requested be included in such Underwritten Registration and the aggregate number of Registrable Securities that the
Holders have requested to be included in such Underwritten Registration, which can be sold without exceeding the Maximum Number of Securities;
(C) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A) and (B), the shares
of Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of
Securities; and (D) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A),
(B) and (C), the shares of Common Stock or other equity securities for the account of other persons or entities that the Company is obligated
to register pursuant to separate written contractual arrangements with such persons or entities, which can be sold without exceeding the
Maximum Number of Securities.
2.2.3 Piggyback Registration
Withdrawal. Any Holder of Registrable Securities shall have the right to withdraw from a Piggyback Registration for any or no reason
whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of his, her or its intention to withdraw
from such Piggyback Registration prior to the effectiveness of the Registration Statement filed with the Commission with respect to such
Piggyback Registration or, in the case of a Piggyback Registration pursuant to a Shelf Registration, the filing of the applicable “red
herring” prospectus or prospectus supplement with respect to such Piggyback Registration used for marketing such transaction. The
Company (whether on its own good faith determination or as the result of a request for withdrawal by persons pursuant to separate written
contractual obligations) may withdraw or abandon a Registration Statement filed with the Commission or Shelf takedown in connection with
a Piggyback Registration at any time prior to the effectiveness of such Registration Statement. Notwithstanding anything to the contrary
in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with the Piggyback Registration
as provided in Section 3.2 prior to its withdrawal under this subsection 2.2.3.
2.2.4 Limitations
on Registration Rights. Under no circumstances shall the Company be obligated to effect more than an aggregate of three (3) Registrations
pursuant to a Demand Registration under Section 2.1 with respect to any or all Registrable Securities, provided that
a Piggyback Registration under this Section 2.2 shall not be counted as a Registration pursuant to a Demand Registration
effected under Section 2.1.
2.3 Registrations
on Form S-3. The Holders of Registrable Securities may at any time, and from time to time, request in writing that the Company, pursuant
to Rule 415 under the Securities Act (or any successor rule promulgated thereafter by the Commission), register the resale of any or all
of their Registrable Securities on Form S-3 or any similar short form registration statement that may be available at such time (“Form
S-3”); provided, however, that the Company shall not be obligated to effect such request through
an Underwritten Offering. Within five (5) days of the Company’s receipt of a written request from a Holder or Holders of Registrable
Securities for a Registration on Form S-3, the Company shall promptly give written notice of the proposed Registration on Form S-3 to
all other Holders of Registrable Securities, and each Holder of Registrable Securities who thereafter wishes to include all or a portion
of such Holder’s Registrable Securities in such Registration on Form S-3 shall so notify the Company, in writing, within ten (10)
days after the receipt by the Holder of the notice from the Company. As soon as practicable thereafter, but not more than sixty (60) days
after the Company’s initial receipt of such written request for a Registration on Form S-3, the Company shall register all or such
portion of such Holder’s Registrable Securities as are specified in such written request, together with all or such portion of Registrable
Securities of any other Holder or Holders joining in such request as are specified in the written notification given by such Holder or
Holders; provided, however, that the Company shall not be obligated to effect any such Registration pursuant to Section
2.3 hereof if (i) a Form S-3 is not available for such offering; or (ii) the Holders of Registrable Securities, together with
the Holders of any other equity securities of the Company entitled to inclusion in such Registration, propose to sell the Registrable
Securities and such other equity securities (if any) at any aggregate price to the public of less than $10,000,000.
2.4 Restrictions
on Registration Rights. If (A) during the period starting with the date sixty (60) days prior to the Company’s good faith estimate
of the date of the filing of, and ending on a date one hundred and twenty (120) days after the effective date of, a Company initiated
Registration and provided that the Company has delivered written notice to the Holders prior to receipt of a Demand Registration pursuant
to subsection 2.1.1 and it continues to actively employ, in good faith, all commercially reasonable efforts to cause
the applicable Registration Statement to become effective; (B) the Holders have requested an Underwritten Registration and the Company
and the Holders are unable to obtain the commitment of underwriters to firmly underwrite the offer; or (C) in the good faith judgment
of the Board such Registration would be seriously detrimental to the Company and the Board concludes as a result that it is essential
to defer the filing of such Registration Statement at such time, then in each case the Company shall furnish to such Holders a certificate
signed by the Chairman of the Board stating that in the good faith judgment of the Board it would be seriously detrimental to the Company
for such Registration Statement to be filed in the near future and that it is therefore essential to defer the filing of such Registration
Statement. In such event, the Company shall have the right to defer such filing for a period of not more than ninety (90) days.
ARTICLE III
COMPANY PROCEDURES
3.1 General Procedures.
If the Company is required to effect the Registration of Registrable Securities pursuant to this Agreement, the Company shall use its
commercially reasonable efforts to effect such Registration to permit the sale of such Registrable Securities in accordance with the intended
plan of distribution thereof, and pursuant thereto the Company shall:
3.1.1 prepare and file with
the Commission as soon as practicable a Registration Statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such Registration Statement to become effective and remain effective until all Registrable Securities covered by such
Registration Statement have been sold or have ceased to be Registrable Securities;
3.1.2 prepare and file with
the Commission such amendments and post-effective amendments to the Registration Statement, and such supplements to the Prospectus, as
may be reasonably requested by the Holders or any Underwriter of Registrable Securities or as may be required by the rules, regulations
or instructions applicable to the registration form used by the Company or by the Securities Act or rules and regulations thereunder to
keep the Registration Statement effective until all Registrable Securities covered by such Registration Statement are sold in accordance
with the intended plan of distribution set forth in such Registration Statement or supplement to the Prospectus or have ceased to be Registrable
Securities;
3.1.3 not later than five
(5) days prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto, furnish without charge to the
Underwriters, if any, and the Holders of Registrable Securities included in such Registration, and such Holders’ legal counsel,
copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case
including all exhibits thereto and documents incorporated by reference therein), the Prospectus included in such Registration Statement
(including each preliminary Prospectus), and such other documents as the Underwriters and the Holders of Registrable Securities included
in such Registration or the legal counsel for any such Holders may reasonably request in order to facilitate the disposition of the Registrable
Securities owned by such holders, provided, that the Company shall have no obligation to furnish any documents publicly filed or furnished
with the Commission pursuant to the Electronic Data Gathering Analysis and Retrieval System (“EDGAR”);
3.1.4 prior to any public
offering of Registrable Securities, use its commercially reasonable efforts to (i) register or qualify the Registrable Securities covered
by the Registration Statement under such securities or “blue sky” laws of such jurisdictions in the United States as the Holders
of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) may request (or provide
evidence reasonably satisfactory to such Holders that the Registrable Securities are exempt from such registration or qualification) and
(ii) take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved
by such other governmental authorities as may be necessary by virtue of the business and operations of the Company and do any and all
other acts and things that may be necessary or advisable to enable the Holders of Registrable Securities included in such Registration
Statement to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however,
that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required
to qualify or take any action to which it would be subject to general service of process or taxation in any such jurisdiction where it
is not then otherwise so subject;
3.1.5 use its commercially
reasonable efforts to cause all such Registrable Securities included in any registration to be listed on such exchanges or otherwise designated
for trading in the same manner as similar securities issued by the Company are then listed or designated or, if no such similar securities
are then listed or designated, in a manner satisfactory to the holders of a majority-in-interest of the Registrable Securities included
in such registration;
3.1.6 provide a transfer
agent as applicable, and registrar for all such Registrable Securities no later than the effective date of such Registration Statement;
3.1.7 advise each seller
of such Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order
by the Commission suspending the effectiveness of such Registration Statement or the initiation or threatening of any proceeding for such
purpose and promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if
such stop order should be issued;
3.1.8 notify the Holders
at any time when a Prospectus relating to such Registration Statement is required to be delivered under the Securities Act, of the happening
of any event as a result of which the Prospectus included in such Registration Statement, as then in effect, includes a Misstatement,
and then to correct such Misstatement as set forth in Section 3.4 hereof;
3.1.9 permit a representative
of the Holders (such representative to be selected by a majority of the participating Holders), the Underwriters, if any, and any attorney
or accountant retained by such Holders or Underwriter to participate, at each such person’s own expense, in the preparation of the
Registration Statement, and cause the Company’s officers, directors and employees to supply all information reasonably requested
by any such representative, Underwriter, attorney or accountant in connection with the Registration; provided, however,
that such representatives or Underwriters enter into a confidentiality agreement, in form and substance reasonably satisfactory to the
Company, prior to the release or disclosure of any such information;
3.1.10 obtain a “comfort”
letter from the Company’s independent registered public accountants in the event of an Underwritten Registration which the participating
Holders may rely on, in customary form and covering such matters of the type customarily covered by “comfort” letters for
transactions of its type as the managing Underwriter may reasonably request, and reasonably satisfactory to a majority-in-interest of
the participating Holders;
3.1.11 on the date the Registrable
Securities are delivered for sale pursuant to such Registration, to the extent customary for a transaction of its type, obtain an opinion,
dated such date, of counsel representing the Company for the purposes of such Registration, addressed to the Holders, the placement agent
or sales agent, if any, and the Underwriters, if any, covering such legal matters with respect to the Registration in respect of which
such opinion is being given as the Holders, placement agent, sales agent, or Underwriter may reasonably request and as are customarily
included in such opinions and negative assurance letters;
3.1.12 in the event of any
Underwritten Offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing
Underwriter of such offering;
3.1.13 make available to
its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12) months beginning
with the first day of the Company’s first full calendar quarter after the effective date of the Registration Statement which satisfies
the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder (or any successor rule promulgated thereafter
by the Commission), and which requirement will be deemed to be satisfied if the Company timely files complete and accurate information
on Forms 10-Q, 10-K or 8-K under the Exchange Act and otherwise complies with Rule 158 under the Securities Act;
3.1.14 if the Registration
involves the Registration of Registrable Securities involving gross proceeds in excess of $60,000,000, use its commercially reasonable
efforts to make available senior executives of the Company to participate in customary “road show” presentations that may
be reasonably requested by the Underwriter in such Underwritten Offering; and
3.1.15 otherwise, in good
faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the Holders, consistent with the terms
of this Agreement, in connection with such Registration.
Notwithstanding the foregoing,
the Company shall not be required to provide any documents or information to an Underwriter, broker, sales agent or placement agent if
such Underwriter, broker, sales agent or placement agent has not then been named with respect to the applicable Underwritten Offering
or other offering involving a Registration as an Underwriter, broker, sales agent or placement agent, as applicable.
3.2 Registration
Expenses. Except as otherwise provided herein, the Registration Expenses of all Registrations shall be borne by the Company. It is
acknowledged by the Holders that the Holders shall bear all incremental selling expenses relating to the sale of Registrable Securities,
such as Underwriters’ commissions and discounts, brokerage fees, Underwriter marketing costs and, other than as set forth in the
definition of “Registration Expenses,” all reasonable fees and expenses of any legal counsel representing the Holders.
3.3 Requirements
for Participation in Underwritten Offerings. Notwithstanding anything in this Agreement to the contrary, if any Holder does not provide
the Company with its requested Holder Information, the Company may exclude such Holder’s Registrable Securities from the applicable
Registration Statement or Prospectus if the Company determines, based on the advice of counsel, that it is necessary or advisable to review
such information prior to filing, or include such information in, the applicable Registration Statement or Prospectus and such Holder
continues thereafter to withhold such information. In addition, no person may participate in any Underwritten Offering for equity securities
of the Company pursuant to a Registration initiated by the Company hereunder unless such person (i) agrees to sell such person’s
securities on the basis provided in any underwriting arrangements approved by the Company and (ii) completes and executes all customary
questionnaires, powers of attorney, indemnities, lock-up agreements, underwriting agreements and other customary documents as may be reasonably
required under the terms of such underwriting arrangements.
3.4 Suspension of
Sales; Adverse Disclosure. Upon receipt of written notice from the Company that a Registration Statement or Prospectus contains a
Misstatement, each of the Holders shall forthwith discontinue disposition of Registrable Securities until it has received copies of a
supplemented or amended Prospectus correcting the Misstatement (it being understood that the Company hereby covenants to prepare and file
such supplement or amendment as soon as reasonably practicable after the time of such notice), or until it is advised in writing by the
Company that the use of the Prospectus may be resumed. If the filing, initial effectiveness or continued use of a Registration Statement
in respect of any Registration at any time would (a) require the Company to make an Adverse Disclosure, (b) require the inclusion in such
Registration Statement of financial statements that are unavailable to the Company for reasons beyond the Company’s control, or
(c) in the good faith judgment of the majority of the Board such Registration, would be seriously detrimental to the Company and the majority
of the Board concludes as a result that it is essential to defer such filing, initial effectiveness or continued use at such time, the
Company may, upon giving prompt written notice of such action to the Holders, delay the filing or initial effectiveness of, or suspend
use of, such Registration Statement for the shortest period of time reasonably practicable, but in no event more than ninety (90) days,
determined in good faith by the Company to be necessary for such purpose. In the event the Company exercises its rights under the preceding
sentence, the Holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the Prospectus relating
to any Registration in connection with any sale or offer to sell Registrable Securities until such Holder receives written notice from
the Company that such sales or offers of Registrable Securities may be resumed, and in each case maintain the confidentiality of such
notice and its contents. The Company shall as promptly as reasonably practicable notify the Holders of the expiration of any period during
which it exercised its rights under this Section 3.4.
3.5 Reporting Obligations.
As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company under the Exchange
Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports required
to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange
Act and to promptly furnish the Holders with true and complete copies of all such filings; provided that any documents publicly filed
or furnished with the Commission pursuant to EDGAR shall be deemed to have been furnished or delivered to the Holders pursuant to this Section
3.5. The Company further covenants that it shall take such further action as any Holder may reasonably request, all to the extent
required from time to time to enable such Holder to sell shares of Common Stock held by such Holder without registration under the Securities
Act within the limitation of the exemptions provided by Rule 144 promulgated under the Securities Act (or any successor rule promulgated
thereafter by the Commission), including providing any legal opinions. Upon the request of any Holder, the Company shall deliver to such
Holder a written certification of a duly authorized officer as to whether it has complied with such requirements.
ARTICLE IV
LOCK-UP
4.1 Lock-up.
4.1.1 Except as permitted
by Section 4.2, the Legacy Citius Oncology Equityholder and each Sponsor Equityholder (each, a “Lock-up Party”)
shall not Transfer any shares of Common Stock or any security convertible into or exercisable or exchanged for Common Stock
beneficially owned or owned of record by such Holder (the “Lock-up”) until the date that is the earlier of (A)
six (6) months after the date hereof or (B) if the last sale price of the Common Stock equals or exceeds $12.00 per share (as adjusted
for share splits, share capitalizations, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading
days within any 30-trading day period commencing at least 150 days after the date hereof, or (y) the date following the date hereof on
which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of
its stockholders having the right to exchange their shares of Common Stock for cash, securities or other property (the “Lock-up Period”).
4.2 Exceptions.
The provisions of Section 4.1 shall not apply to:
4.2.1 transactions relating
to shares of Common Stock or warrants acquired in open market transactions after the date hereof;
4.2.2 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as a bona fide gift or charitable contribution;
4.2.3 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to a trust, family limited partnership
or other entity formed for estate planning purposes for the primary benefit of the spouse, domestic partner, parent, sibling, child or
grandchild of a Holder or any other person with whom a Holder has a relationship by blood, marriage or adoption not more remote than first
cousin and Transfers to any such family member;
4.2.4 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock by will or intestate succession or the
laws of descent and distributions upon the death of a Holder (it being understood and agreed that the appointment of one or more executors,
administrators or personal representatives of the estate of a Holder shall not be deemed a Transfer hereunder to the extent
that such executors, administrators and/or personal representatives comply with the terms of this Article IV on
behalf of such estate);
4.2.5 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pursuant to a qualified domestic order
or in connection with a divorce settlement;
4.2.6 if a Holder is a corporation,
partnership (whether general, limited or otherwise), limited liability company, trust or other business entity, (i) Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to another corporation, partnership,
limited liability company, trust or other business entity that controls, is controlled by or is under common control or management with
a Holder (including, for the avoidance of doubt, where such Holder is a partnership, to its general partner or a successor partnership
or fund, or any other funds managed by such partnership), or (ii) Transfers of shares of Common Stock or any security convertible into
or exercisable or exchangeable for Common Stock as part of a dividend, distribution, transfer or other disposition of shares of Common
Stock to partners, limited liability company members, direct or indirect stockholders or other equity holders of a Holder, including,
for the avoidance of doubt, where such Holder is a partnership, to its general partner or a successor partnership, fund or investment
vehicle, or any other partnerships, funds or investment vehicles controlled or managed by such partnership;
4.2.7 if the Holder is a
trust, Transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to a trustor
or beneficiary of such trust or to the estate of a beneficiary of such trust;
4.2.8 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to the Company’s or the Holder’s
officers, directors, members, consultants or their affiliates;
4.2.9 pledges of shares of
Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as security or collateral in connection
with any borrowing or the incurrence of any indebtedness by any Holder (provided such borrowing or incurrence of indebtedness is secured
by a portfolio of assets or equity interests issued by multiple issuers);
4.2.10 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pursuant to a bona fide third-party
tender offer, merger, asset acquisition, stock sale, recapitalization, consolidation, business combination or other transaction or series
of related transactions involving a Change in Control of the Company, provided that in the event that such tender offer, merger,
asset acquisition, stock sale, recapitalization, consolidation, business combination or other such transaction is not completed, the securities
subject to this Agreement shall remain subject to this Agreement;
4.2.11 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to the Company in connection with the
liquidation or dissolution of the Company by virtue of the laws of the state of the Company’s organization and the Company’s
organizational documents;
4.2.12 the establishment
of a trading plan pursuant to Rule 10b5-1 promulgated under the Exchange Act, provided that such plan does not provide
for the Transfer of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock
during the Lock-up Period; and
4.2.13 Transfers of shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to satisfy any U.S. federal, state, or
local income tax obligations of the Lock-up Party (or its direct or indirect owners) arising from a change in the U.S. Internal
Revenue Code of 1986, as amended (the “Code”), or the U.S. Treasury Regulations promulgated thereunder (the
“Regulations”) after the date on which the Merger Agreement was executed by the parties, and such change prevents
the Merger from qualifying as a “reorganization” pursuant to Section 368 of the Code (and the Merger does not qualify for
similar tax-free treatment pursuant to any successor or other provision of the Code or Regulations taking into account such
changes), in each case solely and to the extent necessary to cover any tax liability as a direct result of the transaction; and
4.2.14 to the extent a waiver
from the Lock-up is required in order for the Company to meet the applicable Nasdaq initial or continued listing rules with respect to
the minimum number of unrestricted round lot holders, as determined by the Company in good faith.
4.3 Null and Void.
If any Transfer of shares of Common Stock prior to the end of the Lock-up Period is made or attempted contrary to
the provisions of this Agreement, such purported Transfer shall be null and void ab initio, and the Company shall
refuse to recognize any such purported transferee as one of its equityholders for any purpose.
ARTICLE V
INDEMNIFICATION AND CONTRIBUTION
5.1 Indemnification.
5.1.1 The Company agrees
to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers and directors and each person who controls
such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities and out-of-pocket expenses (including
actual, reasonable and documented attorneys’ fees) caused by any untrue or alleged untrue statement of material fact contained in
any Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as
the same are caused by or contained in any information furnished in writing to the Company by such Holder expressly for use therein. The
Company shall indemnify the Underwriters, their officers and directors and each person who controls such Underwriters (within the meaning
of the Securities Act) to the same extent as provided in the foregoing with respect to the indemnification of the Holder.
5.1.2 In connection with
any Registration Statement in which a Holder of Registrable Securities is participating, such Holder shall furnish to the Company in writing
such information and affidavits as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus
(the “Holder Information”) and, to the extent permitted by law, shall indemnify the Company, its directors and
officers and agents and each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages,
liabilities and out-of-pocket expenses (including without limitation actual, reasonable and documented attorneys’ fees) resulting
from any untrue or alleged untrue statement of material fact contained in the Registration Statement, Prospectus or preliminary Prospectus
or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein not misleading, but only to the extent that such untrue statement is contained in (or not contained
in, in the case of an omission) any information or affidavit so furnished in writing by such Holder expressly for use therein; provided, however,
that the obligation to indemnify shall be several, not joint and several, among such Holders of Registrable Securities, and the liability
of each such Holder of Registrable Securities shall be in proportion to and limited to the net proceeds received by such Holder from the
sale of Registrable Securities pursuant to such Registration Statement. The Holders of Registrable Securities shall indemnify the Underwriters,
their officers, directors and each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent
as provided in the foregoing with respect to indemnification of the Company.
5.1.3 Any person entitled
to indemnification herein shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification
(provided that the failure to give prompt notice shall not impair any person’s right to indemnification hereunder to the extent
such failure has not materially prejudiced the indemnifying party) and (ii) unless in such indemnified party’s reasonable judgment
a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying
party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the
indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but such
consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim
shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying party with
respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified
party and any other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified
party, consent to the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money
(and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect
to such claim or litigation.
5.1.4 The indemnification
provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of the indemnified
party or any officer, director or controlling person of such indemnified party and shall survive the transfer of securities. The Company
and each Holder of Registrable Securities participating in an offering also agrees to make such provisions as are reasonably requested
by any indemnified party for contribution to such party in the event the Company’s or such Holder’s indemnification is unavailable
for any reason.
5.1.5 If the indemnification
provided under Section 5.1 hereof from the indemnifying party is unavailable or insufficient to hold harmless an indemnified
party in respect of any losses, claims, damages, liabilities and out-of-pocket expenses referred to herein, then the indemnifying party,
in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result of
such losses, claims, damages, liabilities and out-of-pocket expenses in such proportion as is appropriate to reflect the relative fault
of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the
indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by (or not
made by, in the case of an omission), or relates to information supplied by (or not supplied by, in the case of an omission), such indemnifying
party or indemnified party, and the indemnifying party’s and indemnified party’s relative intent, knowledge, access to information
and opportunity to correct or prevent such action; provided, however, that the liability of any Holder under this subsection
5.1.5 shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability.
The amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject
to the limitations set forth in subsections 5.1.1, 5.1.2 and 5.1.3 above, any legal or other
fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree
that it would not be just and equitable if contribution pursuant to this subsection 5.1.5 were determined by pro rata
allocation or by any other method of allocation, which does not take account of the equitable considerations referred to in this subsection
5.1.5. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution pursuant to this subsection 5.1.5 from any person who was not guilty of such fraudulent
misrepresentation.
ARTICLE VI
MISCELLANEOUS
6.1 Notices.
Any notice or communication under this Agreement must be in writing and given by (i) deposit in the United States mail, addressed to the
party to be notified, postage prepaid and registered or certified with return receipt requested, (ii) delivery in person or by courier
service providing evidence of delivery, or (iii) transmission by hand delivery, electronic mail, telecopy, telegram or facsimile. Each
notice or communication that is mailed, delivered, or transmitted in the manner described above shall be deemed sufficiently given, served,
sent, and received, in the case of mailed notices, on the third business day following the date on which it is mailed and, in the case
of notices delivered by courier service, hand delivery, electronic mail, telecopy, telegram or facsimile, at such time as it is delivered
to the addressee or at such time as delivery is refused by the addressee upon presentation. Any notice or communication under this Agreement
must be addressed, if to the Company, to: 11 Commerce Drive, First Floor Cranford, NJ 07016, and, if to any Holder, at such Holder’s
address or facsimile number as set forth in the Company’s books and records. Any party may change its address for notice at any
time and from time to time by written notice to the other parties hereto, and such change of address shall become effective thirty (30)
days after delivery of such notice as provided in this Section 6.1.
6.2 Assignment; No
Third Party Beneficiaries.
6.2.1 This Agreement and
the rights, duties and obligations of the Company hereunder may not be assigned or delegated by the Company in whole or in part.
6.2.2 Prior to the expiration
of the Lock-up Period, no Holder may assign or delegate such Holder’s rights, duties or obligations under this Agreement, in whole
or in part, except in connection with a transfer of Registrable Securities by such Holder to a Permitted Transferee but only if such Permitted
Transferee agrees to become bound by the transfer restrictions set forth in this Agreement.
6.2.3 This Agreement and
the provisions hereof shall be binding upon and shall inure to the benefit of each of the parties and its successors and the permitted
assigns of the Holders, which shall include Permitted Transferees.
6.2.4 This Agreement shall
not confer any rights or benefits on any persons that are not parties hereto, other than as expressly set forth in this Agreement and Section
6.2 hereof.
6.2.5 No assignment by any
party hereto of such party’s rights, duties and obligations hereunder shall be binding upon or obligate the Company unless and until
the Company shall have received (i) written notice of such assignment as provided in Section 6.1 hereof and (ii) the
written agreement of the assignee, in a form reasonably satisfactory to the Company, to be bound by the terms and provisions of this Agreement
(which may be accomplished by an addendum or certificate of joinder to this Agreement). Any transfer or assignment made other than as
provided in this Section 6.2 shall be null and void.
6.3 Counterparts.
This Agreement may be executed in multiple counterparts (including facsimile or PDF counterparts), each of which shall be deemed an original,
and all of which together shall constitute the same instrument, but only one of which need be produced.
6.4 Governing Law;
Venue. NOTWITHSTANDING THE PLACE WHERE THIS AGREEMENT MAY BE EXECUTED BY ANY OF THE PARTIES HERETO, THE PARTIES EXPRESSLY AGREE THAT
(I) THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED UNDER THE LAWS OF THE STATE OF DELAWARE AS APPLIED TO AGREEMENTS AMONG DELAWARE
RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN DELAWARE, WITHOUT REGARD TO THE CONFLICT OF LAW PROVISIONS OF SUCH JURISDICTION
AND (II) THE VENUE FOR ANY ACTION TAKEN WITH RESPECT TO THIS AGREEMENT SHALL BE THE COURT
OF CHANCERY OF THE STATE OF DELAWARE OR, IF UNDER APPLICABLE LAW, EXCLUSIVE JURISDICTION OVER SUCH MATTER IS VESTED IN THE FEDERAL COURTS,
ANY FEDERAL COURT IN THE STATE OF DELAWARE AND ANY APPELLATE COURT FROM ANY THEREOF.
6.5 Amendments and
Modifications. Upon the written consent of the Company and the Holders of at least a majority in interest of the Registrable Securities
at the time in question, compliance with any of the provisions, covenants and conditions set forth in this Agreement may be waived, or
any of such provisions, covenants or conditions may be amended or modified; provided, however, that notwithstanding
the foregoing, any amendment hereto or waiver hereof that adversely affects one Holder, solely in its capacity as a holder of the shares
of the Company, in a manner that is materially different from the other Holders (in such capacity) shall require the consent of the Holder
so affected. No course of dealing between any Holder or the Company and any other party hereto or any failure or delay on the part of
a Holder or the Company in exercising any rights or remedies under this Agreement shall operate as a waiver of any rights or remedies
of any Holder or the Company. No single or partial exercise of any rights or remedies under this Agreement by a party shall operate as
a waiver or preclude the exercise of any other rights or remedies hereunder or thereunder by such party.
6.6 Other Registration
Rights. The Company represents and warrants that no person, other than a Holder of Registrable Securities, has any right to require
the Company to register any securities of the Company for sale or to include such securities of the Company in any Registration filed
by the Company for the sale of securities for its own account or for the account of any other person. Further, the Company represents
and warrants that this Agreement supersedes any other registration rights agreement or agreement with similar terms and conditions and
in the event of a conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.
6.7 Term. This
Agreement shall terminate upon the earlier of (i) the fifth (5th) anniversary of the date of this Agreement or (ii) the date
as of which (A) all of the Registrable Securities have been sold pursuant to a Registration Statement (but in no event prior to the applicable
period referred to in Section 4(a)(3) of the Securities Act and Rule 174 thereunder (or any successor rule promulgated thereafter by the
Commission)) or (B) the Holders of all Registrable Securities are permitted to sell the Registrable Securities under Rule 144 (or any
similar provision) under the Securities Act without limitation on the amount of securities sold or the manner of sale. The provisions
of Section 3.5 and Article V shall survive any termination.
[SIGNATURE PAGES FOLLOW]
IN WITNESS WHEREOF, the undersigned have caused this Agreement
to be executed as of the date first written above.
COMPANY: |
|
CITIUS ONCOLOGY, INC.
|
|
By: |
/s/ Xiaofeng Yuan |
|
Name: |
Xiaofeng Yuan |
|
Title: |
Chief Executive Officer and Chairman |
|
|
|
|
SPONSOR EQUITYHOLDERS: |
|
|
|
10XYZ HOLDINGS LP
|
|
By: |
/s/ Taylor Zhang |
|
Name: |
Taylor Zhang on behalf of
10XYZ Management LLC as General Partner |
|
|
|
|
INTELLIGENT INVESTMENTS I LLC |
|
|
|
|
By: |
/s/ Mark Crone |
|
Name: |
Mark Crone |
|
Title: |
Managing Member |
|
|
|
|
LEGACY CITIUS ONCOLOGY EQUITYHOLDER:
CITIUS PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Leonard Mazur |
|
Name: |
Leonard Mazur |
|
Title: |
Chief Executive Officer and Chairman of the Board |
|
[Signature Page to A&R Registration Rights
Agreement]
16
Exhibit 10.2
EXECUTION VERSION
AMENDED AND RESTATED SHARED SERVICES AGREEMENT
THIS AMENDED AND RESTATED SHARED
SERVICES AGREEMENT (this “Agreement”) is made as of August 9,
2023, by and between Citius Oncology Sub, Inc., a Delaware corporation (the “Company”), and Citius Pharmaceuticals,
Inc, a Delaware corporation (“Citius”) (the Company and Citius may be referred
to herein individually as a “Party” or collectively as the “Parties”).
WHEREAS, prior to the effectiveness
of the Merger (as defined below) Citius owned 100% of the outstanding equity of the Company;
WHEREAS, the Parties have entered
into an Agreement and Plan of Merger and Reorganization by and among Citius, the Company, TenX Keane Acquisition (“TenX”),
and TENX MERGER SUB, INC. (“Merger Sub”) dated as of October 23, 2023 (the “Merger Agreement”),
pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation
(the “Merger”);
WHEREAS, as of time the Merger
becomes effective pursuant to the Merger Agreement (the “Effective Time”), Citius will own at least 80% of the outstanding
equity of TenX (which will be renamed Citius Oncology, Inc.);
WHEREAS, the Parties are entering
into this Agreement concurrently with the closing of the Merger;
WHEREAS, in connection with
the closing of the Merger, the Company has been renamed from Citius Oncology, Inc. to Citius Oncology Sub, Inc.;
WHEREAS, the Company does not
have any employees, office space or operations of its own and does not expect to for the foreseeable future;
WHEREAS, on the terms and subject
to the conditions contained in this Agreement, the Company desires to obtain certain management and scientific services from Citius, and
Citius has agreed to perform such management and scientific services;
WHEREAS, the Company has requested,
and Citius has agreed, for Citius to provide administrative and scientific services to the Company, pursuant to the terms of this Agreement;
and
WHEREAS, this Agreement has
been approved by the Company’s Board of Directors and by Citius’s Board of Directors.
NOW, THEREFORE, in consideration
of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Parties hereto agree as follows:
1. Effectiveness.
Effective as of the Effective Time, this Agreement hereby amends, restates, and replaces in its entirety the Shared Services Agreement
between Citius and the Company dated as of April 1, 2022 (the “Original Agreement”).
2. Management and Scientific
Services.
2.1 Services.
Subject to any limitations imposed by applicable law or regulation, Citius shall render or cause to be rendered management and scientific
services to the Company, which services may include advice and assistance concerning any and all aspects of the operations, executive
management, pre-clinical and clinical trials, regulatory development, manufacturing and the regulatory approval process, accounting, financial
planning and strategic transactions and financings of the Company and conducting relations on behalf of the Company with accountants,
attorneys, financial advisors and other professionals (collectively, the “Services”). Exhibit A sets
forth the Services Citius will provide to the Company as of the Effective Time, which Services are substantially similar to the Services
provided or procured by Citius and used in the operation of the business of the Company immediately prior to the Effective Time. Citius
shall provide and devote to the performance of this Agreement such employees and agents of Citius as Citius shall deem appropriate to
the furnishing of the Services hereunder.
Citius shall devote such time
and efforts to the performance of Services contemplated hereby as Citius deems reasonably necessary or appropriate; provided, however,
that no minimum number of hours is required to be devoted by Citius on a weekly, monthly, annual or other basis. The Company acknowledges
that Citius’s Services are not exclusive to the Company and that Citius may render similar Services to other persons and entities.
Citius covenants that the
Services will be performed in a diligent, timely, efficient, workmanlike and commercially reasonable manner and in a fashion designed
to support the business of the Company in substantially the same manner and to substantially the same standard as the business is conducted
prior to the Effective Time, and, with respect to specific Services, in accordance with the standards, if any, set forth on Exhibit
A with respect to such Services or as otherwise agreed. In performing the Services, Citius agrees that part of its responsibilities
shall be to review, to the extent applicable, the regulations and laws applicable to the Services to be provided hereunder, and to reflect
any such regulations, laws or requirements in the performance of Services to the Company.
Citius may change operational
aspects of the Services or the way in which they are provided, or substitute them with other services, so long as the Services are provided
or procured to substantially the same standards as they were provided immediately prior to the Effective Time. If changes or substitutions
are made, Citius shall use reasonable efforts so that:
| (i) | the Services are not disrupted; and |
| | |
| (ii) | the change or substitution does not result in an increase in the Service Fees, unless the Company has
agreed to the increase in advance. |
2.2
Freedom to Pursue Opportunities and Limitation on Liability.
2.2.1 Freedom to Pursue
Opportunities. In recognition that the Company and Citius and its wholly owned and partly owned subsidiaries engage and may in the
same or similar activities or lines of business and have an interest in the same general areas of corporate opportunities, and in recognition
of the benefits to be derived by the Company hereunder, each of the Company and Citius wish to guide the conduct of certain affairs of
the Company as they may involve Citius.
Except as Citius may otherwise
agree in writing after the date hereof:
| (i) | Citius will have the right: (A) to directly or indirectly engage in any business including, without limitation,
any business activities or lines of business that are the same as the Company’s or its affiliates or similar to those pursued by
the Company or its affiliates, or (B) to directly or indirectly do business with any client or customer of the Company or its affiliates; provided that
Citius does not compete with the Company in the area of developing treatments for cutaneous T-cell lymphoma or peripheral T-cell lymphoma,
immuno-oncology treatments and other oncology treatments; |
| (ii) | Citius will have no duty (contractual or otherwise) to communicate or present any corporate opportunities
to the Company that do not violate this Section 2.2.1 |
| (iii) | Neither Citius nor any officer, director, employee, partner, member, stockholder, affiliate or associated
entity thereof will be liable to the Company or its affiliates for breach of any duty (contractual or otherwise) by reason of any activities
or omissions of the types referred to in this Section 2.2.1 or of any such person’s participation therein. |
3. Term. Citius
shall provide the Services set forth in Section 2 above from the Effective Time until the earlier of (a) termination
of this Agreement by mutual agreement of Citius and the Company and (b) the 2nd anniversary of this Agreement; provided that
this Agreement shall be automatically extended for additional one-year periods unless Citius or the Company provides written notice of
its desire not to automatically extend the term of this Agreement to the other Parties hereto at least thirty (30) days prior to such
date (such period, the “Term”).
No termination of this Agreement,
whether pursuant to this Section 3 or otherwise, will affect the Company’s duty to pay any Service Fee (as defined
herein in Section 4) accrued, or to reimburse any cost or expense incurred pursuant to Section 5 hereof,
prior to the effective date of such termination. Upon termination of this Agreement, Citius’s right to receive any further Service
Fee or reimbursement for costs and expenses that have not accrued or been incurred to the date of termination shall cease and terminate.
Additionally, the obligations of the Company under Section 5 (Expenses), Section 7 (Indemnification),
the provisions of Section 2.2.2 above (whether in respect of or relating to Services rendered prior to termination of
this Agreement or in respect of or relating to any Services provided after termination of this Agreement), the provisions of Section
9 (Confidentiality) (for the term provided therein) and the provisions of Section 21 (Governing Law) will also
survive any termination of this Agreement to the maximum extent permitted under applicable law.
4. Compensation.
4.1 The Company and Citius agree
that the compensation set forth in this Agreement is being paid to Citius in consideration of the Services provided and the substantial
commitment and effort made by Citius hereunder, and that such fees have been negotiated at arms’ length and are fair, reasonable
and consistent with fair market value. Citius shall be paid a quarterly fee (the “Service Fee”) as set forth on Exhibit
A hereto, which may be amended from time to time upon mutual agreement of the Parties.
4.2 Unless otherwise agreed
by the Parties in writing, any payment pursuant to this Section 4 shall be made in cash by wire transfer(s) of immediately
available funds to or among one or more accounts as designated from time-to-time by Citius to the Company in writing. Citius’s Service
Fee will be invoiced quarterly, in arrears, and the Company shall pay all invoices within thirty (30) days of the date of such invoice.
4.3 It is hereby acknowledged
that the Company shall have no payment obligations hereunder other than as set forth in this Section 4 and in Section
5 for the Services to be performed hereunder (including, without limitation, the Services as set forth on Exhibit A attached
hereto), and the Company’s indemnity obligations to Citius under Section 7.
4.4 In the event any Service
is terminated other than at the end of a payment period under the applicable underlying arrangement, such period’s associated costs
shall be pro-rated based on the number of days in such period prior to the termination date.
5. Expenses. Actual
and direct out-of-pocket expenses reasonably incurred by Citius and its personnel in performing the Services shall be reimbursed to Citius
by the Company upon the delivery to the Company of an invoice, receipt or such other supporting data as the Company reasonably shall require.
Unless otherwise agreed by the Parties in writing, the Company shall reimburse Citius by wire transfer of immediately available funds
for any amount paid by Citius, which shall be in addition to any other amount payable to Citius under this Agreement.
6. Independent Contractor.
Citius shall act solely as an independent contractor and shall have complete charge of its respective personnel engaged in the performance
of the Services under this Agreement. Neither Citius nor its officers, employees or agents will be considered employees or agents of the
Company as a result of this Agreement. As an independent contractor, Citius shall have authority only to act as an advisor to the Company
and shall have no authority to enter into any agreement or to make any representation, commitment or warranty binding upon the Company
or to obtain or incur any right, obligation or liability on behalf of the Company. Nothing contained in this Agreement shall result in
Citius or any of its affiliates or their respective directors, officers, employees or agents being a partner, joint venturer, principal,
agent, fiduciary or beneficiary of the Company.
7. Indemnification.
7.1 Indemnification.
Subject to the applicable limitations set forth in this Section 7, the Company shall indemnify Citius, its affiliates (other
than the Company or TenX) and their respective directors, officers, employees and agents (collectively, the “Citius Indemnified
Party”), to the fullest extent permitted by law, from and against any and all actions, causes of action, suits, claims, liabilities,
losses, damages and costs and expenses in connection therewith, including without limitation reasonable attorneys’ fees and expenses
(“Indemnified Liabilities”) to which the Citius Indemnified Party may become subject, directly or indirectly caused
by, related to or arising out of the Services or any other advice or Services contemplated by this Agreement or the engagement of Citius
pursuant to, and the performance by Citius of the Services contemplated by, this Agreement.
7.2 Subject to the applicable
limitations set forth in this Section 7, Citius shall indemnify the Company, its affiliates (other than Citius) and their
respective directors, officers and employees (collectively, the “Company Indemnified Party”), harmless from and against
any and all Indemnified Liabilities to which the Company Indemnified Party may become subject, directly or indirectly caused by, related
to or arising out based upon or related to the Services performed for the Company hereunder to the extent that any such Indemnified Liabilities
were the result of, arise out of, or are based upon, (i) a breach of the provisions of this Agreement caused by the gross negligence or
intentional misconduct of Citius, or (ii) any action or inaction of Citius, its affiliates or its third party contractors providing the
Services, or their respective directors, officers, employees, contractors or agents at the request, at the direction, or with the consent,
of the Company or any of its directors, officers, employees, representatives or agents.
7.3 An indemnifying party shall
promptly reimburse the respective Indemnified Party for Indemnified Liabilities as incurred, in connection with the investigation of,
preparation for or defense of any pending or threatened claim or any action or proceeding arising therefrom, whether or not such Indemnified
Party is a party and whether or not such claim, action or proceeding is initiated or brought by or on behalf of the Company or Citius
and whether or not resulting in any liability. If and to the extent that the foregoing undertaking may be unenforceable for any reason,
the Parties hereby agree to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that
is permissible under applicable law.
7.4 Limited Liability.
In no event shall either Party be liable under any provision of this Agreement to each or each other’s respective affiliates, directors,
officers, employees or agents for indirect, special, incidental, consequential (including, without limitation, lost profits or savings,
whether or not such damages are foreseeable) or punitive damages; provided, however, that this limitation shall
not apply to any indirect, incidental, consequential (including lost profits) or punitive damages asserted or awarded to any third party
for which Citius would otherwise be responsible under Section 7.2; provided, further, however,
that Citius’s aggregate liability for all claims brought by the Company hereunder shall be limited to the total fees paid to Citius
for the Services provided to the Company through the date of any claim, whether or not such claim arose under this Agreement or the Original
Agreement.
7.5 An indemnifying party shall
not be liable under the indemnification contained in Section 7.1 or 7.2, as applicable, hereof with respect
to an Indemnified Party to the extent that such Indemnified Liabilities are found in a final non-appealable judgment by a court of competent
jurisdiction to have resulted directly from the Indemnified Party’s willful misconduct or gross negligence. The Parties further
agree that no Indemnified Party shall have any liability (whether direct or indirect, in contract, tort or otherwise) to such Indemnified
Party’s securities holders or creditors related to or arising out of the engagement of Citius pursuant to, or the performance by
Citius of the Services contemplated by, this Agreement.
8. Employee Matters.
Citius shall at all times remain the employer of all of its employees performing the Services and Citius shall perform all of the responsibilities
of an employer under applicable federal, state, and local laws and regulations. Citius, as relates to its employees performing Services,
shall be responsible for: (i) selecting and hiring its employees legally, including compliance with all applicable laws in connection
therewith; (ii) the supervision, direction and control of its employees performing Services; (iii) paying its employees’ wages and
other benefits in accordance with applicable laws; (iv) paying or withholding all required payroll taxes and mandated insurance premiums;
(v) providing worker’s compensation coverage for employees as required by law; (vi) fulfilling the employer’s obligations
with respect to unemployment compensation; and (vii) any and all claims of its employees and other personnel arising out of this Agreement
or performance of the Services. Citius shall indemnify, defend and hold harmless the Company from any third-party claim resulting from
a breach by Citius of the foregoing obligations, including, without limitation, any claims made by Citius’s personnel against the
Company alleging rights or benefits as an employee of the Company.
9. Confidentiality.
Citius or the Company (the “Disclosing Party”) may provide the other Party (the “Receiving Party”)
with certain confidential and proprietary information (“Confidential Information”). Confidential Information of a Party
hereto includes, but is not limited to, its product specifications and technical data, product designs/ideas, market/sales forecasts and
information, proprietary materials, suppliers, tooling, all business trade secrets, financial and accounting data, customers and prospective
customers, pricing information, and know-how. However, “Confidential Information” does not include information that (i) is
publicly known at the time of its disclosure or becomes publicly known thereafter through no fault of the Receiving Party, (ii) is lawfully
received by the Receiving Party from a third party not under an obligation of confidentiality to the Disclosing Party, (iii) is published
or otherwise made known to the public by the Disclosing Party, or (iv) was generated independently by the Receiving Party without the
use of the Confidential Information provided by the Disclosing Party.
The Receiving Party will refrain
from using the Disclosing Party’s Confidential Information for any purpose other than in connection with providing the Services
contemplated by this Agreement. The Receiving Party may only disclose the Disclosing Party’s Confidential Information to the Receiving
Party’s officers, directors, key employees, and financial and legal advisors (collectively, “Representatives”)
who have the need to know such Confidential Information in order for the Receiving Party to perform its obligations under this Agreement.
Such Representatives will be informed of and will agree to be bound by the provisions of this Section (or other terms and conditions that
are no less protective of the Discloser’s Confidential Information than the terms herein), and the Receiving Party will remain responsible
for any unauthorized use or disclosure of the Disclosing Party’s Confidential Information by its Representatives. The Receiving
Party may also disclose the Disclosing Party’s Confidential Information pursuant to the requirement or request of a governmental
agency, a court or administrative subpoena, or an order or other legal process or requirement of law so long as it shall (i) first notify
the Disclosing Party of such request or requirement, (ii) in the case of a required disclosure, furnish only such portion of the Disclosing
Party’s Confidential Information as it is advised in writing by counsel that it is legally required to disclose, and (iii) cooperate
with the Disclosing Party in its efforts to obtain an order or other reliable assurance that confidential treatment will be accorded to
that portion of the Disclosing Party’s Confidential Information that is required to be disclosed.
Within seven (7) days after
the termination or expiration of this Agreement or after written request of the Disclosing Party, the Receiving Party shall promptly (i)
return or destroy all Confidential Information of the Disclosing Party and all copies thereof, (ii) destroy all of its files and memoranda
prepared based on the Disclosing Party’s Confidential Information, and (iii) provide the Disclosing Party with a written certification
that all such information and materials have been returned or destroyed. Notwithstanding the foregoing, the Receiving Party may retain
archival copies of the Disclosing Party’s Confidential Information in accordance with policies and procedures designed to comply
with legal, regulatory, and professional requirements, solely to demonstrate compliance therewith. This Section 9 shall
survive the expiration or termination of this Agreement for a period of three (3) years; provided, however, that
for any Confidential Information that constitutes a trade secret (as defined by applicable law), the obligations of this Section
9 shall survive until such Confidential Information is no longer a trade secret.
10. Intellectual Property.
10.1 Intellectual Property.
Except as expressly set forth in Section 10.2, solely as between the Parties, all right, title and interest in and to all
intellectual property, including, without limitation, each and every invention, discovery, design, drawing, protocol, process, technique,
formula, trade secret, device, compound, substance, material, pharmaceutical, method, software program (including, without limitation,
object code, source code, flow charts, algorithms and related documentation), listing, routine, manual and specification, whether or not
patentable or copyrightable, that are made, developed, perfected, designed, conceived or first reduced to practice, either solely or jointly
with others in the performance of the Services conducted under this Agreement or the Original Agreement by Citius’s employees, agents,
consultants, subcontractors or other representatives, but specifically excluding Citius Background Technology (as defined below), (collectively
“Work Product”), will be owned solely by the Company, and Citius hereby assigns to the Company any and all rights that
Citius may have in the Work Product. Citius represents and warrants to the Company that each employee, agent, consultant and subcontractor
of Citius providing Services hereunder is obligated to assign all of his/her/its right, title and interest in and to Work Product to Citius.
Citius and all employees, agents, consultants and subcontractors of Citius shall execute and deliver to the Company all writings and do
all such things as may be necessary or appropriate to vest in the Company all right, title and interest in and to Work Product. Citius
shall disclose to the Company in a timely manner any Work Product arising under this Agreement or the Original Agreement. Excluding Citius’s
Background Technology (as defined in Section 10.2), the Company may, in its sole discretion, file and prosecute in its own
name and at its own expense, patent applications on any patentable inventions within the Work Product. Upon the request of the Company,
and at the Company’s expense, Citius will assist the Company in the preparation, filing and prosecution of such patent applications
and will execute and deliver any and all instruments necessary to effectuate the ownership of such patent applications and to enable the
Company to file and prosecute such patent applications in any country.
10.2 Citius Background
Technology. Notwithstanding anything to the contrary contained in this Agreement or the Original Agreement, Work Product shall exclude
(a) any Citius proprietary technology existing prior to April 1, 2022 or that is developed or acquired by Citius independent of the Services
performed pursuant to this Agreement or the Original Agreement and (b) any modifications, enhancements or improvements to any of the foregoing
that are or were developed by Citius in the course of performing the Services (collectively, “Citius Background Technology”),
and, as between the Parties, all Citius Background Technology shall be and remain the sole and exclusive property of Citius. Citius hereby
grants the Company a non-exclusive, perpetual, irrevocable, worldwide, royalty-free license, including the right to sublicense through
multiple tiers of sublicense, to use the Citius Background Technology that is embodied within the Work Product solely if and to the extent
necessary for the exploitation of the Work Product. For clarity, Work Product shall not include any industry know-how that is created
by Citius hereunder which is broadly applicable to the businesses of both Citius and the Company at the time of creation, such as processes,
techniques and methods.
10.3 Force Majeure. Neither
Party shall be liable or responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement, for any failure
or delay in fulfilling or performing any term of this Agreement (except for any obligations to make payments to the other Party hereunder),
when and to the extent such failure or delay is caused by or results from acts beyond the impacted Party’s (“Impacted
Party”) reasonable control, including, without limitation, the following force majeure
event (“Force Majeure”): (a) acts of God; (b) flood, fire, earthquake, other potential disasters or catastrophes, such
as epidemics, pandemics, or quarantines, or explosion; (c) war, invasion, hostilities (whether war is declared or not), terrorist threats
or acts, riot, or other civil unrest; (d) government order, law, or actions; (e) embargoes, or blockades in effect on or after the date
of this Agreement; (f) national or regional emergency; (g) strikes, labor stoppages or slowdowns, or other industrial disturbances; (h)
shortage of adequate power or transportation facilities; and (i) any other similar events or circumstances beyond the reasonable control
of the Impacted Party. Notwithstanding the foregoing, the Impacted Party will use good faith efforts to complete performance or correct
any default or breach upon removal of any Force Majeure event that caused such delay in performance, default or breach.
11. Reports and Records.
Citius shall, upon request from the Company, and within a reasonable amount of time, provide the Company with a detailed report of Services
performed on its behalf. Citius shall, upon request from the Company, and within a reasonable amount of time, provide the Company with
copies of documents relevant to this Agreement and the Services and reasonably required or requested by the Company, including without
limitation books, records and accounts. The Parties shall maintain records of all costs and expenses incurred and shared pursuant to this
Agreement in a manner that satisfies the record keeping requirements of federal income tax regulations and generally accepted accounting
principles.
12. Non-solicitation.
The Parties agree that during the term of this Agreement and for a period of twenty-four (24) months following the termination or expiration
of this Agreement, neither Party shall directly or indirectly solicit, hire, recruit, or attempt to do so, any of the employees of the
other Party without written consent of the other Party; provided, however, this Section 13 shall
not preclude either Party from (A) making general or public solicitations not targeted at any employees of the other Party or (B) hiring
any such employee of the other Party who has ceased being an employee, consultant or independent contractor for at least twelve (12) months.
13. Covenants.
Each Party represents, warrants and covenants to the other Party that: (i) such Party has the full power and authority to enter into this
Agreement and to perform its obligations hereunder, without the need for any consents; and (ii) such Party’s execution of and performance
under this Agreement shall not breach any oral or written agreement with any third party or any obligation owed by the Party to any third
party.
14. Notices. All
notices, demands, or other communications to be given or delivered by reason of the provisions of this Agreement shall be in writing and
shall be deemed to have been given or made when (i) delivered personally to the recipient, (ii) telecopied to the recipient (with a hard
copy sent to the recipient by reputable overnight courier service (charges prepaid)) if telecopied before 5:00 p.m. Eastern Standard Time
on a business day, and otherwise on the next business day, (iii) one (1) business day after being sent to the recipient by reputable overnight
courier service (charges prepaid) or (iv) received via electronic mail by the recipient if received via electronic mail before 5:00 p.m.
Eastern Standard Time on a business day, and otherwise on the next business day after such receipt. Such notices, demands and other communications
shall be sent to the address for such recipient indicated below or to such other address or to the attention of such other person as the
recipient party has specified by prior written notice to the sending party.
Notices to Citius
11 Commerce Drive, 1st Floor
Cranford, NJ 07016
Attn: Leonard Mazur - CEO
lmazur@citiuspharma.com
Notices to the Company:
11 Commerce Drive, 1st Floor
Cranford, NJ 07016
Attn: Jaime Bartushak - CFO
jbartushak@citiuspharma.com
15. Severability.
If any term, provision, covenant or restriction of this Agreement is held by a
court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions
set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the Parties hereto
shall use their best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the Parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any such terms, provisions, covenants and
restrictions which may be hereafter declared invalid, illegal, void or unenforceable.
16. Entire Agreement.
This Agreement and the Merger Agreement contain the entire understanding of the Parties with respect to the subject matter hereof and
supersede any prior communication or agreement with respect thereto.
17. Counterparts.
This Agreement may be executed in multiple counterparts, and any Party may execute any such counterpart, each of which when executed and
delivered will thereby be deemed to be an original and all of which counterparts taken together will constitute one and the same instrument.
The delivery of this Agreement may be effected by means of an exchange of facsimile or portable document format (.pdf) signatures.
18. Amendments and
Waiver. No amendment or waiver of any term, provision or condition of this Agreement will be effective, unless in writing and executed
by both the Company and Citius. No waiver on any one occasion will extend to, effect or be construed as a waiver of any right or remedy
on any future occasion. No course of dealing of any person nor any delay or omission in exercising any right or remedy will constitute
an amendment of this Agreement or a waiver of any right or remedy of any Party hereto.
19. Successors and
Assigns. All covenants and agreements contained in this Agreement by or on behalf of any of the Parties hereto will bind and inure
to the benefit of the respective successors and permitted assigns of the Parties hereto whether so expressed or not. Neither the Company
nor Citius may assign its rights or delegate its obligations hereunder without the prior written consent of the other Party, which consent
shall not be unreasonably withheld.
20. Governing Law.
This Agreement shall be governed by and construed in accordance with the substantive laws of the State of Delaware, without giving effect
to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other
than the State of Delaware.
21. Waiver of Jury
Trial. To the extent not prohibited by applicable law which cannot be waived, each of the Parties hereto hereby waives, and covenants
that it will not assert (whether as plaintiff, defendant or otherwise), any right to trial by jury in any forum in respect of any issue,
claim, demand, cause of action, action, suit or proceeding arising out of or based upon this Agreement or the subject matter hereof, in
each case whether now existing or hereafter arising and whether in contract or tort or otherwise. Any of the Parties hereto may file an
original counterpart or a copy of this Agreement with any court as written evidence of the consent of each of the Parties hereto to the
waiver of its right to trial by jury.
22. Third Party Beneficiaries.
This Agreement is not intended to confer on any person or entity except the Parties any rights or remedies hereunder.
23. No Strict Construction.
The Parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question
of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the Parties hereto, and no presumption or
burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.
24. Headings: Interpretation.
The headings in this Agreement are for convenience and reference only and shall not limit or otherwise affect the meaning hereof. The
use of the word “including” in this Agreement will be by way of example rather than by limitation.
[SIGNATURE PAGES FOLLOW]
IN WITNESS WHEREOF, the Parties
hereto have executed this Amended and Restated Shared Services Agreement as of the date first written above.
|
COMPANY:
CITIUS ONCOLOGY SUB, INC. |
|
|
|
|
By: |
/s/ Leonard Mazur |
|
Name: |
Leonard Mazur |
|
Title: |
Chief Executive Officer and Chairman of the Board |
|
|
|
|
CITIUS:
|
|
CITIUS PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Leonard Mazur |
|
Name: |
Leonard Mazur |
|
Title: |
Chief Executive Officer and Chairman of the Board |
[Signature Page to Amended and Restated Shared
Services Agreement]
EXHIBIT A
SERVICES
Exhibit 10.8
Citius Pharmaceuticals, Inc.
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
EXECUTION VERSION
August 12, 2024
Citius Oncology, Inc. (formerly, TenX Keane Acquisition)
420 Lexington Avenue, Suite 2446
New York, New York 10170
Attention: Taylor Zhang
Email: tzhang@ascendantga.com
Dear Mr. Zhang:
This letter agreement (this
“Letter Agreement”) is sent in reference to that certain Agreement and Plan of Merger and Reorganization, dated
October 23, 2023 (the “Merger Agreement”), by and among Citius Oncology, Inc., a Delaware corporation and formerly
TenX Keane Acquisition, a Cayman Islands exempted company (“Parent”), TenX Merger Sub, Inc., a Delaware corporation
(“Merger Sub”), Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”)
and Citius Oncology Sub, Inc., a Delaware corporation formerly known as Citius Oncology, Inc. (“SpinCo”), for
purposes of (1) setting forth the understanding of the parties to the Merger Agreement with respect to certain provisions thereof, (2)
confirming the waiver by Parent and Merger Sub of certain provisions of the Merger Agreement, and (3) confirming the waiver by Company
and SpinCo of certain provisions of the Merger Agreement, in each case in accordance with the terms and conditions set forth in this Letter
Agreement. Capitalized terms used but not otherwise defined in this Letter Agreement shall have the meanings ascribed to them in the Merger
Agreement.
| (i) | Each of Parent and Merger Sub hereby irrevocably waive in their entirety the requirements contained in
Section 7.18(a) and Section 7.18(b) of the Merger Agreement pursuant to which, prior to the Closing, the Company and SpinCo
are required to (a) enter into a transfer and assignment agreement, in a form reasonably satisfactory to Parent and the Company, pursuant
to which the Company will transfer the LYMPHIRTM (denileukin diftitox) trademark or trademark application, as applicable, and
SpinCo will accept such transfer and assignment, with such assignment and transfer automatically effective for all purposes as of the
effective date of the Company FDA Letter and the SpinCo FDA Letter, and (b) promptly following the Company’s receipt of the Notice
of Approval, but in no event later than five (5) Business Days thereafter, deliver to the FDA an executed Company FDA Letter and an executed
SpinCo FDA Letter. For the avoidance of doubt, the Company and the Surviving Corporation shall, within sixty (60) days following the Closing
Date, (I) enter into a transfer and assignment agreement, in a form reasonably satisfactory to the Company and the Surviving Corporation,
pursuant to which the Company will transfer the LYMPHIRTM (denileukin diftitox) trademark or trademark application, as applicable,
and the Surviving Corporation will accept such transfer and assignment and (II) in connection therewith, deliver to the FDA an executed
Company FDA Letter and an executed SpinCo FDA Letter. |
| (ii) | Each of Parent and Merger Sub hereby irrevocably waive in their entirety the (a) requirements contained
in Section 2.3(f) of the Merger Agreement pursuant to which on the Closing Date, in connection with the Effective Time, the Company
is required to pay or cause to be paid, by wire transfer of immediately available funds to Parent, $10,000,000 (the “Working
Capital Amount”) as a capital contribution to Parent for purposes of funding working capital of the Surviving Corporation,
and (b) the provisions of Section 7.16(b)(iii) of the Merger Agreement, which state that upon the Closing, the Company will be
repaid by Parent an amount equal to the portion of the Extension Fees that the Company paid either to Sponsor (or its designee) or into
the Trust Account, but only if at the time of the Closing the balance of the Trust Account equals or exceeds $2,000,000; provided,
however, that each such waiver is conditioned upon the Company paying, or causing to be paid, $10,000,000 in accordance with the
provisions of that certain Flow of Funds Memorandum, dated as of even date herewith, by and among Parent, Merger Sub, the Company, SpinCo
and Sponsor (the “Funds Flow”). The Company and SpinCo hereby acknowledge and agree that the execution and delivery
of the Funds Flow as of the date hereof satisfies in full the Parent’s obligation to deliver a written statement at least two (2)
Business Days prior to the Closing Date setting forth the Parent Estimated Transaction Expenses pursuant to Section 2.3(c) of the Merger
Agreement. For the avoidance of doubt, the Company shall not be responsible for, and shall have no obligation to pay, any Parent Estimated
Transaction Expenses or Parent Transaction Expenses, except to the extent expressly set forth in the Funds Flow. |
| (iii) | Each of Parent and Merger Sub hereby irrevocably waive in their entirety the requirements contained in
Section 10.1 of the Merger Agreement pursuant to which Parent is obligated, at least 48 hours prior to the Effective Time, to provide
notice to the Trustee in accordance with the Trust Agreement and deliver any other documents, opinions or notices required to be delivered
to the Trustee pursuant to the Trust Agreement, and cause the Trustee as of the Effective Time to transfer all funds held in the Trust
Account to Parent (to be held as available cash on the balance sheet of Parent, and to be used for working capital and other general corporate
purposes of the business following the Closing), and thereafter to cause the Trust Account and the Trust Agreement to terminate; provided,
however, that such waiver is conditioned on, at least 48 hours prior to the Effective Time, Parent providing notice to the Trustee
in accordance with the Trust Agreement, and delivering any other documents, opinions or notices required to be delivered to the Trustee
pursuant to the Trust Agreement, and causing the Trustee as of the Effective Time to transfer all funds held in the Trust Account to the
Company (for use by the Company for such purposes as the Company may determine in its sole discretion), and thereafter causing the Trust
Account and the Trust Agreement to terminate. |
Each of the Parties hereby
acknowledges and agrees that this Letter Agreement was entered into in accordance with the provisions of Section 10.7(a) of the
Merger Agreement. No Party may assert that a condition precedent in the Merger Agreement (including, without limitation, any conditions
set forth in in Section 8.3(a) or Section 8.3(e) of the Merger Agreement) has not been satisfied for failure to comply with
the covenants that the Parties have waived pursuant to this Letter Agreement.
Except as expressly modified
by this Letter Agreement, the Merger Agreement shall remain in full force and effect in accordance with the terms thereof. In the event
of a conflict between the provisions of this Letter Agreement and the Merger Agreement, this Letter Agreement shall control. Sections
10.3, 10.4, 10.7, 10.8, 10.9, 10.10, 10.11, and 10.12 of the Merger Agreement shall
apply to this Letter Agreement mutatis mutandis.
[Signature page follows]
|
Sincerely, |
|
|
|
CITIUS PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Leonard Mazur |
|
Name: |
Leonard Mazur |
|
Title: |
Chief Executive Officer and Chairman of the Board |
Acknowledged, agreed to and accepted: |
|
|
|
CITIUS ONCOLOGY SUB, Inc., |
|
formerly known as Citius Oncology, Inc. |
|
|
|
|
By: |
/s/ Leonard Mazur |
|
Name: |
Leonard Mazur |
|
Title: |
Chief Executive Officer and Chairman of the Board |
|
|
|
|
CITIUS ONCOLOGY, INC., |
|
formerly TenX Keane Acquisition |
|
|
|
|
By: |
/s/ Xiaofeng Yuan |
|
Name: |
Xiaofeng Yuan |
|
Title: |
Chief Executive Officer and Chairman |
|
|
|
|
TENX MERGER SUB, INC. |
|
|
|
|
By: |
/s/ Xiaofeng Yuan |
|
Name: |
Xiaofeng Yuan |
|
Title: |
Chief Executive Officer and Chairman |
|
[Signature Page – Side Letter to Agreement
and Plan of Merger and Reorganization]
CC:
The Crone Law Group
420 Lexington Avenue, Suite 2446
New York, New York 10170
Attn: Tammara Fort; Samara Thomas
Email: tfort@cronelawgroup.com; sthomas@cronelawgroup.com
Wyrick Robbins Yates & Ponton LLP
4101 Lake Boone Trail, Suite 300
Raleigh, North Carolina 27607
Attention: Alec Donaldson; David P. Creekman
Email: adonaldson@wyrick.com; dcreekman@wyrick.com
4
Exhibit 10.9
PROMISSORY NOTE
Principal Amount: $3,800,111
Date: August 16, 2024
Citius Oncology, Inc., a Delaware
corporation (the “Payor”), promises to pay to the order of Citius Pharmaceuticals, Inc., a Nevada corporation or its
registered assigns or successors in interest (the “Payee”), or order, the principal sum of Three Million Eight Hundred
Thousand One Hundred and Eleven Dollars ($3,800,111) on the Maturity Date (as defined below) in lawful money of the United States of America,
on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available
funds to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.
1. Principal.
The entire unpaid principal balance of this Note shall be payable on the date on which Payor has closed a capital raise of at least
$10 million through the issuance of debt or equity securities or the royalty-backed monetization of LYMPHIR™ (the “Maturity
Date”). The principal balance may be prepaid. Under no circumstances shall any individual, including but not limited to any
officer, director, employee or shareholder of the Payor, be obligated personally for any obligations or liabilities of the Payor hereunder.
2. Interest. No
interest shall accrue on the unpaid principal balance of this Note.
3. Events
of Default. The following shall constitute an event of default (“Event of Default”):
(a) Failure
by Payor to pay the principal amount due pursuant to this Note.
(b) The commencement
by Payor of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the
consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other
similar official) of Payor or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors,
or the failure of Payor generally to pay its debts as such debts become due, or the taking of corporate action by Payor in furtherance
of any of the foregoing.
(c) The entry
of a decree or order for relief by a court having jurisdiction in the premises in respect of Payor in an involuntary case under any applicable
bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar
official) of Payor or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance
of any such decree or order unstayed and in effect for a period of 60 consecutive days.
(d) The Payor fails
to perform or comply with any one or more of its obligations under this Note.
(e) Any present
or future indebtedness of the Payor in respect of moneys borrowed or raised becomes (or becomes capable of being declared) due and payable
prior to its stated maturity by reason of any event of default, or any such indebtedness is not paid when due or, as the case may be,
within any applicable grace period.
(f) A distress,
attachment, execution or other legal process is levied or enforced on or against any assets of the Payor which is not discharged or stayed
within 30 days.
(g) It is or becomes
unlawful for the Payor to perform any of its obligations under this Note, or any obligations of the Payor under this Note are not or cease
to be legal, valid, binding or enforceable.
4. Remedies.
(a) Upon the occurrence of
an Event of Default specified in Section 3(a) hereof, Payee may, by written notice to Payor, declare this Note to be
due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become
immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived,
anything contained herein or in the documents evidencing the same to the contrary notwithstanding.
(b) Upon the occurrence of
an Event of Default specified in Sections 3(b) or 3(c), the unpaid principal balance of this Note, and all
other amounts payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action
on the part of Payee.
5. Waivers. Payor
and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and
notice of protest with regard to this Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms
of this Note, and all benefits that might accrue to Payor by virtue of any present or future laws exempting any property, real or personal,
or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for
any stay of execution, exemption from civil process, or extension of time for payment; and Payor agrees that any real estate that may
be levied upon pursuant to a judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ
in whole or in part in any order desired by Payee.
6. Unconditional
Liability. Payor hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement
of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party,
and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to
by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect
to the payment or other provisions of this Note, and agrees that additional Payors, endorsers, guarantors, or sureties may become parties
hereto without notice to Payor or affecting Payor’s liability hereunder. Any failure of Payee to exercise any right hereunder shall
not be construed as a waiver of the right to exercise the same or any other right at any time and from time to time thereafter. Payee
may accept late payments, or partial payments, even though marked “payment in full” or containing words of similar import
or other conditions, without waiving any of its rights.
7. Notices. All
notices, statements or other documents which are required or contemplated by this Note shall be: in writing and delivered (i) personally
or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to the address
designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address or fax number as may
be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently provided to such party
or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted
shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation,
if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days
after mailing if sent by mail.
8. Construction. THIS
NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS
THEREOF.
9. Severability. Any
provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
10. Amendment; Waiver. Any
amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Payor and the Payee.
11. Assignment. This
Note binds and is for the benefit of the successors and permitted assigns of Payor and the Payee. No assignment or transfer of this Note
or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent
of the other party hereto and any attempted assignment without the required consent shall be void.
[Signature page follows]
IN WITNESS WHEREOF,
Payor, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first
above written.
Citius
Oncology, Inc.
|
|
|
|
By: |
/s/ Leonard Mazur |
|
Name: |
Leonard Mazur |
|
Title: |
Chairman and Chief Executive Officer |
|
4
Exhibits 16.1
August 16, 2024
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Citius Oncology,
Inc. (formerly known as TenX Keane Acquisition) under Item 4.01 of its Form 8-K dated August 12, 2024. We agree with the statements concerning
our Firm under Item 4.01 in such Form 8-K; we are not in a position to agree or disagree with other statements of Citius Oncology, Inc.
(formerly known as TenX Keane Acquisition) contained therein.
Very truly yours,
/s/ Marcum llp
Marcum llp
Exhibit 21.1
List of Subsidiaries of Citius Oncology, Inc.
Name
of Subsidiary |
|
Jurisdiction
of Incorporation |
Citius
Oncology Sub, Inc. |
|
Delaware |
v3.24.2.u1
Cover
|
Aug. 12, 2024 |
Entity Addresses [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 12, 2024
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-41534
|
Entity Registrant Name |
Citius Oncology, Inc.
|
Entity Central Index Key |
0001851484
|
Entity Tax Identification Number |
99-4362660
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
11 Commerce Drive
|
Entity Address, Address Line Two |
1st Floor
|
Entity Address, City or Town |
Cranford
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
07016
|
City Area Code |
908
|
Local Phone Number |
967-6677
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock
|
Trading Symbol |
CTOR
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Former Address [Member] |
|
Entity Addresses [Line Items] |
|
Entity Registrant Name |
TenX Keane Acquisition
|
Entity Address, Address Line One |
420 Lexington Avenue
|
Entity Address, Address Line Two |
Suite 2446
|
Entity Address, City or Town |
New York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10170
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
dei_EntityAddressesLineItems |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
TenX Keane Acquisition (NASDAQ:TENKU)
Historical Stock Chart
From Sep 2024 to Oct 2024
TenX Keane Acquisition (NASDAQ:TENKU)
Historical Stock Chart
From Oct 2023 to Oct 2024